AptarGroup (ATR) 10-Q26 Oct 232023 Q3 Quarterly reportFinancial data

Company Profile

COVER

COVER - shares	9 Months Ended
COVER - shares	Sep. 30, 2023	Oct. 20, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-3853103
Entity Address, Address Line One	265 EXCHANGE DRIVE
Entity Address, Address Line Two	SUITE 301
Entity Address, City or Town	CRYSTAL LAKE
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		65,781,269
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000896622
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Sales	$ 892,997	$ 836,860	$ 2,648,970	$ 2,526,335
Operating Expenses:
Cost of sales (exclusive of depreciation and amortization shown below)	566,691	546,376	1,697,824	1,638,114
Selling, research & development and administrative	138,137	135,428	427,488	416,351
Depreciation and amortization	62,686	57,601	184,212	174,818
Restructuring initiatives	6,161	2,270	19,628	2,989
Total Operating Expenses	773,675	741,675	2,329,152	2,232,272
Operating Income	119,322	95,185	319,818	294,063
Other (Expense) Income:
Interest expense	(9,984)	(9,756)	(29,900)	(30,668)
Interest income	946	752	2,266	2,029
Net investment (loss) gain	(1,240)	649	1,839	(1,084)
Equity in results of affiliates	1,002	178	1,514	(184)
Miscellaneous income (expense), net	3	(2,093)	(1,341)	(3,144)
Total Other Expense	(9,273)	(10,270)	(25,622)	(33,051)
Income before Income Taxes	110,049	84,915	294,196	261,012
Provision for Income Taxes	25,751	30,738	72,265	80,851
Net Income	84,298	54,177	221,931	180,161
Net (Gain) Loss Attributable to Noncontrolling Interests	(2)	67	201	131
Net Income Attributable to AptarGroup, Inc.	$ 84,296	$ 54,244	$ 222,132	$ 180,292
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic (in dollars per share)	$ 1.28	$ 0.83	$ 3.39	$ 2.75
Diluted (in dollars per share)	$ 1.26	$ 0.81	$ 3.32	$ 2.70
Average Number of Shares Outstanding:
Basic (in shares)	65,707	65,322	65,550	65,446
Diluted (in shares)	67,035	66,581	66,865	66,825
Dividends per Common Share (in dollars per share)	$ 0.41	$ 0.38	$ 1.17	$ 1.14

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income	$ 84,298	$ 54,177	$ 221,931	$ 180,161
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	(52,514)	(92,164)	(28,639)	(184,051)
Changes in derivative gains (losses), net of tax	2,707	3,542	(2,424)	3,663
Defined benefit pension plan, net of tax
Actuarial (loss) gain, net of tax	(5)	31	63	(719)
Amortization of prior service cost included in net income, net of tax	33	25	98	78
Amortization of net loss included in net income, net of tax	161	1,551	483	4,703
Total defined benefit pension plan, net of tax	189	1,607	644	4,062
Total other comprehensive loss	(49,618)	(87,015)	(30,419)	(176,326)
Comprehensive Income (Loss)	34,680	(32,838)	191,512	3,835
Comprehensive Loss Attributable to Noncontrolling Interests	88	910	319	1,750
Comprehensive Income (Loss) Attributable to AptarGroup, Inc.	$ 34,768	$ (31,928)	$ 191,831	$ 5,585

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets
Cash and equivalents	$ 151,573	$ 141,732
Accounts and notes receivable, less current expected credit loss ("CECL") of $12,209 in 2023 and $9,519 in 2022	717,484	676,987
Inventories	490,872	486,806
Prepaid and other	142,829	124,766
Total Current Assets	1,502,758	1,430,291
Land	29,421	30,197
Buildings and improvements	718,242	693,542
Machinery and equipment	3,022,026	2,925,517
Property, Plant and Equipment, Gross	3,769,689	3,649,256
Less: Accumulated depreciation	(2,381,041)	(2,305,592)
Property, Plant and Equipment, Net	1,388,648	1,343,664
Investments in equity securities	48,022	52,308
Goodwill	943,037	945,632
Intangible assets, net	287,231	315,744
Operating lease right-of-use assets	53,510	58,675
Miscellaneous	75,018	57,144
Total Other Assets	1,406,818	1,429,503
Total Assets	4,298,224	4,203,458
Current Liabilities:
Notes payable, revolving credit facility and overdrafts	124,503	3,810
Current maturities of long-term obligations, net of unamortized debt issuance costs	366,378	118,981
Accounts payable, accrued and other liabilities	740,759	794,385
Total Current Liabilities	1,231,640	917,176
Long-Term Obligations, net of unamortized debt issuance costs	680,065	1,052,597
Deferred income taxes	17,448	20,563
Retirement and deferred compensation plans	57,433	48,977
Operating lease liabilities	39,697	42,948
Deferred and other non-current liabilities	58,252	52,993
Commitments and contingencies	0	0
Total Deferred Liabilities and Other	172,830	165,481
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 71.5 million and 70.9 million shares issued as of September 30, 2023 and December 31, 2022, respectively	715	709
Capital in excess of par value	1,028,663	968,618
Retained earnings	2,074,434	1,929,240
Accumulated other comprehensive loss	(371,440)	(341,366)
Less: Treasury stock at cost, 5.7 million and 5.6 million shares as of September 30, 2023 and December 31, 2022, respectively	(532,633)	(503,266)
Total AptarGroup, Inc. Stockholders’ Equity	2,199,739	2,053,935
Noncontrolling interests in subsidiaries	13,950	14,269
Total Stockholders’ Equity	2,213,689	2,068,204
Total Liabilities and Stockholders’ Equity	$ 4,298,224	$ 4,203,458

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Accounts and notes receivable, allowance for credit loss (in dollars)	$ 12,209	$ 9,519
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	199,000,000	199,000,000
Common stock, shares issued (in shares)	71,500,000	70,900,000
Treasury stock (in shares)	5,700,000	5,600,000

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock Par Value	Treasury Stock	Capital in Excess of Par Value	Non- Controlling Interest
Beginning balance at Dec. 31, 2021	$ 1,984,600	$ 1,789,413	$ (316,041)	$ 704	$ (421,203)	$ 916,534	$ 15,193
Increase (Decrease) in Stockholders' Equity
Net income (loss)	180,161	180,292					(131)
Foreign currency translation adjustments	(184,051)		(182,432)				(1,619)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	4,062		4,062
Changes in derivative gains (losses), net of tax	3,663		3,663
Stock awards and option exercises	46,675			3	8,729	37,943
Cash dividends declared on common stock	(74,656)	(74,656)
Treasury stock purchased	(72,329)				(72,329)
Ending balance at Sep. 30, 2022	1,888,125	1,895,049	(490,748)	707	(484,803)	954,477	13,443
Beginning balance at Jun. 30, 2022	1,948,464	1,865,634	(404,576)	706	(467,550)	939,897	14,353
Increase (Decrease) in Stockholders' Equity
Net income (loss)	54,177	54,244					(67)
Foreign currency translation adjustments	(92,164)		(91,321)				(843)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	1,607		1,607
Changes in derivative gains (losses), net of tax	3,542		3,542
Stock awards and option exercises	16,569			1	1,988	14,580
Cash dividends declared on common stock	(24,829)	(24,829)
Treasury stock purchased	(19,241)				(19,241)
Ending balance at Sep. 30, 2022	1,888,125	1,895,049	(490,748)	707	(484,803)	954,477	13,443
Beginning balance at Dec. 31, 2022	2,068,204	1,929,240	(341,366)	709	(503,266)	968,618	14,269
Increase (Decrease) in Stockholders' Equity
Net income (loss)	221,931	222,132					(201)
Foreign currency translation adjustments	(28,639)	(227)	(28,294)				(118)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	644		644
Changes in derivative gains (losses), net of tax	(2,424)		(2,424)
Stock awards and option exercises	67,986			6	7,935	60,045
Cash dividends declared on common stock	(76,711)	(76,711)
Treasury stock purchased	(37,302)				(37,302)
Ending balance at Sep. 30, 2023	2,213,689	2,074,434	(371,440)	715	(532,633)	1,028,663	13,950
Beginning balance at Jun. 30, 2023	2,188,426	2,017,065	(321,913)	713	(526,484)	1,005,007	14,038
Increase (Decrease) in Stockholders' Equity
Net income (loss)	84,298	84,296					2
Foreign currency translation adjustments	(52,514)	(1)	(52,423)				(90)
Changes in unrecognized pension gains (losses) and related amortization, net of tax	189		189
Changes in derivative gains (losses), net of tax	2,707		2,707
Stock awards and option exercises	25,772			2	2,114	23,656
Cash dividends declared on common stock	(26,926)	(26,926)
Treasury stock purchased	(8,263)				(8,263)
Ending balance at Sep. 30, 2023	$ 2,213,689	$ 2,074,434	$ (371,440)	$ 715	$ (532,633)	$ 1,028,663	$ 13,950

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows from Operating Activities:
Net Income	$ 221,931	$ 180,161
Adjustments to reconcile net income to net cash provided by operations:
Depreciation	150,718	142,046
Amortization	33,494	32,772
Stock-based compensation	36,084	31,941
Provision for CECL	3,449	3,344
(Gain) loss on disposition of fixed assets	(3,753)	315
Net (gain) loss on remeasurement of equity securities	(1,839)	1,084
Deferred income taxes	(16,978)	(9,506)
Defined benefit plan expense	10,659	18,367
Equity in results of affiliates	(1,514)	184
Change in fair value of contingent consideration	0	(2,265)
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables	(43,061)	(76,921)
Inventories	(5,188)	(62,139)
Prepaid and other current assets	(19,236)	(9,903)
Accounts payable, accrued and other liabilities	3,860	62,053
Income taxes payable	(8,732)	15,470
Retirement and deferred compensation plan liabilities	1,323	(15,432)
Other changes, net	(5,615)	(5,222)
Net Cash Provided by Operations	355,602	306,349
Cash Flows from Investing Activities:
Capital expenditures	(231,199)	(226,131)
Proceeds from government grants	0	17,058
Proceeds from sale of property, plant and equipment	6,037	778
Maturity of short-term investment	0	740
Acquisition of businesses, net of cash acquired and release of escrow	(16,570)	(4,100)
Acquisition of intangible assets, net	(3,648)	(5,189)
Proceeds from sale of investment in equity securities	5,604	1,599
Notes receivable, net	439	(7,155)
Net Cash Used by Investing Activities	(239,337)	(222,400)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts	24,392	35,058
Repayments of notes payable and overdrafts	(27,863)	(33,417)
Proceeds and (repayments) of short term revolving credit facility, net	123,514	(93,468)
Proceeds from long-term obligations	257	406,550
Repayments of long-term obligations	(117,289)	(262,245)
Debt issuance costs	0	(4,009)
Payment of contingent consideration obligation	(22,750)	0
Dividends paid	(76,711)	(74,656)
Proceeds from stock option exercises	39,742	18,411
Purchase of treasury stock	(37,302)	(72,329)
Net Cash Used by Financing Activities	(94,010)	(80,105)
Effect of Exchange Rate Changes on Cash	(12,914)	(957)
Net Increase in Cash and Equivalents and Restricted Cash	9,341	2,887
Cash and Equivalents and Restricted Cash at Beginning of Period	142,732	122,925
Cash and Equivalents and Restricted Cash at End of Period	152,073	125,812
Cash and equivalents	151,573	124,812
Restricted cash included in prepaid and other	500	1,000
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows	$ 152,073	$ 125,812

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year. ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Topic 405), which enhances the transparency of supplier finance programs and requires certain disclosures for a buyer in a supplier finance program. The requirements are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 13, 2023. Early adoption is permitted. We adopted this guidance in the fourth quarter of 2022. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from LIBOR to SOFR in our revolving credit facility. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements. INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany, the pre-2023 earnings in Suzhou, China and the pre-2020 earnings in Italy, Switzerland and Colombia. The change in the Suzhou, China assertion was made in the current quarter. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements. ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2023, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $37.3 million. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

REVENUE

REVENUE	9 Months Ended
REVENUE	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Segment financial information for the prior periods has been recast to conform to the current presentation. Refer to Note 16 - Segment Information. Revenue by segment and geography based on shipped from locations for the three and nine months ended September 30, 2023 and 2022 was as follows: For the Three Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 252,174 $ 106,804 $ 11,118 $ 19,092 $ 389,188 Aptar Beauty 203,599 58,181 39,963 22,237 323,980 Aptar Closures 53,431 89,795 21,956 14,647 179,829 Total $ 509,204 $ 254,780 $ 73,037 $ 55,976 $ 892,997 For the Three Months Ended September 30, 2022 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 212,751 $ 105,542 $ 6,309 $ 18,795 $ 343,397 Aptar Beauty 169,936 75,070 35,195 22,845 303,046 Aptar Closures 54,146 99,198 21,777 15,296 190,417 Total $ 436,833 $ 279,810 $ 63,281 $ 56,936 $ 836,860 For the Nine Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 733,749 $ 309,946 $ 30,699 $ 61,540 $ 1,135,934 Aptar Beauty 629,168 175,942 113,282 61,564 979,956 Aptar Closures 167,836 261,903 63,128 40,213 533,080 Total $ 1,530,753 $ 747,791 $ 207,109 $ 163,317 $ 2,648,970 For the Nine Months Ended September 30, 2022 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 632,876 $ 320,297 $ 20,503 $ 52,414 $ 1,026,090 Aptar Beauty 540,629 224,269 97,337 67,558 929,793 Aptar Closures 163,424 304,051 62,327 40,650 570,452 Total $ 1,336,929 $ 848,617 $ 180,167 $ 160,622 $ 2,526,335 We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance. The opening and closing balances of our contract asset and contract liabilities were as follows: Balance as of December 31, 2022 Balance as of September 30, 2023 Increase/ Contract asset (current) $ 16,736 $ 19,768 $ 3,032 Contract liability (current) 80,241 73,282 (6,959) Contract liability (long-term) 25,361 32,818 7,457 The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during the current year against contract liabilities is $106.0 million, including $59.4 million relating to contract liabilities at the beginning of the year. Current contract assets are included within the prepaid and Other and Miscellaneous assets, respectively, while current contract liabilities and long-term contract liabilities are included within accounts payable, accrued and other liabilities and deferred and other non-current liabilities, respectively, within our Condensed Consolidated Balance Sheets. Determining the Transaction Price In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled. Product Sales We primarily manufacture and sell drug and consumer product dosing, dispensing and protection technologies. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced at the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer. To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale. There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced. As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties. Tooling Sales We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any significant payment terms as payment is typically either received during the mold-build process or shortly after completion. In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of September 30, 2023 or December 31, 2022. Service Sales We also provide services to our customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation. Contract Costs We do not incur significant costs to obtain or fulfill revenue contracts. Credit Risk We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review. We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.

INVENTORIES

INVENTORIES	9 Months Ended
INVENTORIES	Sep. 30, 2023
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories, by component net of reserves, consisted of: September 30, December 31, Raw materials $ 145,742 $ 159,041 Work in process 173,453 153,592 Finished goods 171,677 174,173 Total $ 490,872 $ 486,806

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amount of goodwill for the nine months ended September 30, 2023 by reporting segment were as follows: Aptar Aptar Aptar Closures Total Balance as of December 31, 2022 $ 498,742 $ 319,011 $ 127,879 $ 945,632 Reclassification due to segment change — (39,472) 39,472 — Acquisitions — 3,655 114 3,769 Foreign currency exchange effects (5,191) (1,025) (148) (6,364) Balance as of September 30, 2023 $ 493,551 $ 282,169 $ 167,317 $ 943,037 The table below shows a summary of intangible assets as of September 30, 2023 and December 31, 2022. September 30, 2023 December 31, 2022 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 9.8 $ 7,181 $ (1,617) $ 5,564 $ 8,044 $ (1,968) $ 6,076 Acquired technology 11.4 136,860 (65,378) 71,482 135,191 (56,628) 78,563 Customer relationships 13.5 304,726 (116,570) 188,156 305,994 (99,130) 206,864 Trademarks and trade names 7.5 44,140 (32,555) 11,585 43,998 (28,190) 15,808 License agreements and other 31.4 16,910 (6,466) 10,444 15,425 (6,992) 8,433 Total intangible assets 13.3 $ 509,817 $ (222,586) $ 287,231 $ 508,652 $ (192,908) $ 315,744 Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2023 and 2022 was $11,400 and $10,678, respectively. Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2023 and 2022 was $33,494 and $32,772, respectively. As of September 30, 2023, future estimated amortization expense for the years ending December 31 is as follows: 2023 $ 11,473 (remaining estimated amortization for 2023) 2024 41,267 2025 39,565 2026 37,287 2027 26,026 Thereafter 131,613

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full-year taxes, adjusted for the impact of discrete quarterly items. The effective tax rate for the three months ended September 30, 2023 and 2022, respectively, was 23.4% and 36.2%. The effective tax rate for the nine months ended September 30, 2023 and 2022, respectively, was 24.6% and 31.0%. The effective tax rate for the three months ended September 30, 2023 reflects additional tax benefits from employee stock-based compensation and a benefit related to a change in the U.S. tax regulations issued during the quarter related to foreign tax credits. The effective tax rate for the three months ended September 30, 2022 reflects an out-of-period charge of $7.2 million for taxes related to a legal entity reorganization to enhance our dividend and cash management capabilities. The tax charge had an 8.5% impact on the effective tax rate for the three months ended September 30, 2022. The lower reported effective tax rate for the nine months ended September 30, 2023 reflects additional tax benefits from employee stock-based compensation, the refining of certain U.S. tax filing positions and a change in the U.S. tax regulations pertaining to foreign tax credits. As mentioned above, the tax rate for the nine months ended September 30, 2022, reflects an out-of-period charge for $7.2 million and had a 2.8% impact on the effective tax rate.

DEBT

DEBT	9 Months Ended
DEBT	Sep. 30, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Notes Payable, Revolving Credit Facility and Overdrafts At September 30, 2023 and December 31, 2022, our notes payable, revolving credit facility and overdrafts consisted of the following: September 30, December 31, Revolving credit facility 4.73% to 6.18% $ 123,790 $ — Overdrafts 4.64% to 4.71% 713 3,810 $ 124,503 $ 3,810 On June 30, 2021, we entered into an amended and restated multi-currency revolving credit facility (the "revolving credit facility") with a syndicate of banks to replace the then-existing facility maturing July 2022 (the "prior credit facility") and to amend and restate the unsecured term loan facility extended to our wholly-owned UK subsidiary under the prior credit facility (as amended, the "amended term facility"). The revolving credit facility matures in June 2026, subject to a maximum of two one-year extensions in certain circumstances, and provides for unsecured financing of up to $600 million available in the U.S. and to our wholly-owned UK subsidiary. The amended term facility matured in July 2022 and was repaid in full. The revolving credit facility can be drawn in various currencies including USD, EUR, GBP, and CHF to the equivalent of $600 million, which may be increased by up to $300 million subject to the satisfaction of certain conditions. As of September 30, 2023, $44.5 million and €75.0 million ($79.3 million) was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of December 31, 2022, no balance was utilized under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. In May 2023 the revolving credit facility was amended to make SOFR the default borrowing rate for USD. The revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. In October 2020, we entered into an unsecured money market borrowing arrangement to provide short term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of September 30, 2023 or December 31, 2022. Long-Term Obligations On July 19, 2023, we repaid in full the €100 million 0.98% Senior Notes that were due July 2023. On March 7, 2022, we issued $400 million aggregate principal amount of 3.60% Senior Notes due March 2032 in an underwritten public offering. The form and terms of the notes were established pursuant to an Indenture, dated as of March 7, 2022, as amended and supplemented by a First Supplemental Indenture, dated as of March 7, 2022, each between the Company and U.S. Bank Trust Company, National Association, as trustee. Interest is payable semi-annually in arrears. The notes are unsecured obligations and rank equally in right of payment with all of our other existing and future senior, unsecured indebtedness. At September 30, 2023 and December 31, 2022, our long-term obligations consisted of the following: September 30, 2023 December 31, 2022 Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031 $ 15,005 $ 29,167 Senior unsecured notes 1.0%, due in 2023 — 106,995 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 100,000 100,000 Senior unsecured notes 1.2%, due in 2024 211,440 213,990 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million 399,128 399,050 Finance Lease Liabilities 24,867 26,934 Unamortized debt issuance costs (3,997) (4,558) $ 1,046,443 $ 1,171,578 Current maturities of long-term obligations (366,378) (118,981) Total long-term obligations $ 680,065 $ 1,052,597 The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are: Year One $ 363,408 Year Two 6,368 Year Three 256,200 Year Four 315 Year Five 72 Thereafter 399,210 Covenants Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at September 30, 2023 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.61 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 16.19 to 1.00 ________________________________________

LEASES

LEASES	9 Months Ended
LEASES	Sep. 30, 2023
Leases [Abstract]
LEASES	LEASES We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2037. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses. The components of lease expense for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost $ 5,150 $ 4,870 $ 15,841 $ 15,605 Finance lease cost: Amortization of right-of-use assets $ 908 $ 1,050 $ 2,686 $ 3,307 Interest on lease liabilities 289 307 883 947 Total finance lease cost $ 1,197 $ 1,357 $ 3,569 $ 4,254 Short-term lease and variable lease costs $ 5,774 $ 4,226 $ 15,883 $ 11,437 Supplemental cash flow information related to leases was as follows: Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 15,993 $ 15,001 Operating cash flows from finance leases 883 941 Financing cash flows from finance leases 2,377 2,749 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 7,764 $ 13,146 Finance leases 401 919
LEASES	LEASES We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2037. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term. Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses. The components of lease expense for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost $ 5,150 $ 4,870 $ 15,841 $ 15,605 Finance lease cost: Amortization of right-of-use assets $ 908 $ 1,050 $ 2,686 $ 3,307 Interest on lease liabilities 289 307 883 947 Total finance lease cost $ 1,197 $ 1,357 $ 3,569 $ 4,254 Short-term lease and variable lease costs $ 5,774 $ 4,226 $ 15,883 $ 11,437 Supplemental cash flow information related to leases was as follows: Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 15,993 $ 15,001 Operating cash flows from finance leases 883 941 Financing cash flows from finance leases 2,377 2,749 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 7,764 $ 13,146 Finance leases 401 919

RETIREMENT AND DEFERRED COMPENS

RETIREMENT AND DEFERRED COMPENSATION PLANS	9 Months Ended
RETIREMENT AND DEFERRED COMPENSATION PLANS	Sep. 30, 2023
Retirement Benefits [Abstract]
RETIREMENT AND DEFERRED COMPENSATION PLANS	RETIREMENT AND DEFERRED COMPENSATION PLANS Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date. Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended September 30, 2023 2022 2023 2022 Service cost $ 2,409 $ 3,948 $ 1,487 $ 1,775 Interest cost 2,158 1,742 915 330 Expected return on plan assets (3,094) (3,228) (589) (653) Amortization of net loss — 1,668 230 403 Amortization of prior service cost — — 45 35 Net periodic benefit cost $ 1,473 $ 4,130 $ 2,088 $ 1,890 Domestic Plans Foreign Plans Nine Months Ended September 30, 2023 2022 2023 2022 Service cost $ 7,228 $ 11,838 $ 4,444 $ 5,621 Interest cost 6,473 5,227 2,735 1,045 Expected return on plan assets (9,283) (9,684) (1,758) (2,069) Amortization of net loss — 5,003 687 1,280 Amortization of prior service cost — — 133 106 Net periodic benefit cost $ 4,418 $ 12,384 $ 6,241 $ 5,983 The components of net periodic benefit cost, other than the service cost component, are included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income. Employer Contributions We currently have no minimum funding requirements for our domestic and foreign plans. There were no contributions to our domestic defined benefit plans during the nine months ended September 30, 2023 and we do not expect significant payments during the rest of 2023. We contributed $1.0 million to our foreign defined benefit plans during the nine months ended September 30, 2023 and do not expect additional significant contributions during the rest of 2023.

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	Sep. 30, 2023
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2021 $ (249,500) $ (66,486) $ (55) $ (316,041) Other comprehensive (loss) income before reclassifications (182,432) (719) 3,617 (179,534) Amounts reclassified from accumulated other comprehensive income (loss) — 4,781 46 4,827 Net current-period other comprehensive (loss) income (182,432) 4,062 3,663 (174,707) Balance - September 30, 2022 $ (431,932) $ (62,424) $ 3,608 $ (490,748) Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive income (loss) before reclassifications (28,294) 63 (2,424) (30,655) Amounts reclassified from accumulated other comprehensive income — 581 — 581 Net current-period other comprehensive income (loss) (28,294) 644 (2,424) (30,074) Balance - September 30, 2023 $ (357,034) $ (5,307) $ (9,099) $ (371,440) Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended September 30, 2023 2022 Defined Benefit Pension Plans Amortization of net loss $ 230 $ 2,071 (1) Amortization of prior service cost 45 35 (1) 275 2,106 Total before tax (81) (530) Tax impact $ 194 $ 1,576 Net of tax Derivatives Changes in cross currency swap: interest component $ — $ (33) Interest Expense Changes in cross currency swap: foreign exchange component — 4,843 Miscellaneous, net $ — $ 4,810 Net of tax Total reclassifications for the period $ 194 $ 6,386 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Nine Months Ended September 30, 2023 2022 Defined Benefit Pension Plans Amortization of net loss $ 687 $ 6,283 (1) Amortization of prior service cost 133 106 (1) 820 6,389 Total before tax (239) (1,608) Tax impact $ 581 $ 4,781 Net of tax Derivatives Changes in cross currency swap: interest component $ — $ (171) Interest Expense Changes in cross currency swap: foreign exchange component — 217 Miscellaneous, net $ — $ 46 Net of tax Total reclassifications for the period $ 581 $ 4,827 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	9 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks. For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets (See Note 11 - Fair Value). Cash Flow Hedge For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows. Net Investment Hedge A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar has an additive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction. On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% U.S. dollar debt to €200 million of fixed-rate 2.5224% euro debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Condensed Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive (loss) income as the swaps are effective in hedging the designated risk. As of September 30, 2023, the fair value of the cross currency swap was a $12.0 million liability. The swap agreement will mature on September 15, 2029. Other As of September 30, 2023, we have recorded the fair value of foreign currency forward exchange contracts of $0.4 million in prepaid and other and $0.3 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. All forward exchange contracts outstanding as of September 30, 2023 had an aggregate notional contract amount of $51.1 million. Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 September 30, 2023 December 31, 2022 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 377 $ — $ 1,107 $ — $ 377 $ — $ 1,107 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 305 $ — $ 269 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 12,049 — 8,840 — $ 12,049 $ 305 $ 8,840 $ 269 __________________________ (1) This cross currency swap agreement is composed of both an interest component and a foreign exchange component. The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, 2023 and 2022 Derivatives Designated as Hedging Instruments Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2023 2022 2023 2022 Cross currency swap agreement: Interest component $ — $ (30) Interest expense $ — $ 33 $ (9,984) Foreign exchange component 2,707 (1,238) Miscellaneous, net — (4,843) 3 $ 2,707 $ (1,268) $ — $ (4,810) The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2023 and 2022 Derivatives Designated as Hedging Instruments Amount of Gain Location of Gain Recognized Amount of Gain Total Amount of Affected Income Statement Line Item 2023 2022 2023 2022 Cross currency swap agreement: Interest component $ — $ 229 Interest expense $ — $ 171 $ (29,900) Foreign exchange component (2,424) 3,388 Miscellaneous, net — (217) (1,341) $ (2,424) $ 3,617 $ — $ (46) The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2023 and 2022 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2023 2022 Foreign Exchange Contracts Other (Expense) Income: $ 44 $ (853) $ 44 $ (853) The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2023 and 2022 Derivatives Not Designated Location of Loss Recognized Amount of Loss 2023 2022 Foreign Exchange Contracts Other (Expense) Income: $ (756) $ (962) $ (756) $ (962) Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount September 30, 2023 Derivative Assets $ 377 — $ 377 — — $ 377 Total Assets $ 377 — $ 377 — — $ 377 Derivative Liabilities $ 12,354 — $ 12,354 — — $ 12,354 Total Liabilities $ 12,354 — $ 12,354 — — $ 12,354 December 31, 2022 Derivative Assets $ 1,107 — $ 1,107 — — $ 1,107 Total Assets $ 1,107 — $ 1,107 — — $ 1,107 Derivative Liabilities $ 9,109 — $ 9,109 — — $ 9,109 Total Liabilities $ 9,109 — $ 9,109 — — $ 9,109

FAIR VALUE

FAIR VALUE	9 Months Ended
FAIR VALUE	Sep. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows: • Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities. • Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets. • Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability. As of September 30, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,532 $ 1,532 $ — $ — Foreign exchange contracts (2) 377 — 377 — Convertible notes 5,650 — — 5,650 Total assets at fair value $ 7,559 $ 1,532 $ 377 $ 5,650 Liabilities Foreign exchange contracts (2) $ 305 $ — $ 305 $ — Cross currency swap contract (2) 12,049 — 12,049 — Total liabilities at fair value $ 12,354 $ — $ 12,354 $ — As of December 31, 2022, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 5,297 $ 5,297 $ — $ — Foreign exchange contracts (2) 1,107 — 1,107 — Convertible note 5,650 — — 5,650 Total assets at fair value $ 12,054 $ 5,297 $ 1,107 $ 5,650 Liabilities Foreign exchange contracts (2) $ 269 $ — $ 269 $ — Cross currency swap contract (2) 8,840 — 8,840 — Contingent consideration obligation 25,310 — — 25,310 Total liabilities at fair value $ 34,419 $ — $ 9,109 $ 25,310 ________________________________________________ (1) Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 18 – Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates. The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $517.3 million as of September 30, 2023 and $868.7 million as of December 31, 2022. During the first quarter of 2022, we invested $5.0 million in a convertible note in Enable Injections, Inc. This investment is recorded at fair value and is a Level 3 fair value measurement. During the second quarter of 2022, we invested $1.0 million in a convertible note in Siklus Refill Pte. Ltd. ("Siklus"). During the fourth quarter of 2022, Siklus repaid $0.4 million of its convertible note. This investment is recorded at fair value and is a Level 3 fair value measurement. As discussed in Note 12 – Fair Value of our Annual Report on Form 10-K for the year ended December 31, 2022, we had contingent consideration obligations to the selling equity holders of: – Fusion Packaging, Inc. ("Fusion") in connection with the acquisition of 100% of the equity interests of Fusion (the "Fusion Acquisition") based on 2022 cumulative performance targets, and – Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as "Noble") in connection with the acquisition of 100% of the equity interests of Noble (the "Noble Acquisition") based on 2024 cumulative performance targets. We consider these obligations a Level 3 liability and estimated the aggregate fair value for these contingent consideration arrangements as follows: September 30, 2023 December 31, 2022 Fusion Acquisition $ — $ 25,310 Noble Acquisition — — $ — $ 25,310 Changes in the fair value of these obligations are recorded within selling, research & development and administrative expenses in our Condensed Consolidated Statements of Income. Significant changes to the inputs, as noted above, can result in a significantly higher or lower fair value measurement. In April 2023, we repaid the outstanding contingent consideration obligation to the selling equity holders of Fusion. Approximately $22.8 million is recorded as a financing activity in our Condensed Consolidated Statements of Cash Flows representing the portion of the outstanding contingent consideration that was associated with the acquisition fair value of the liability. The remaining $2.5 million is recorded within cash flow from operations. The following table provides a summary of changes in our Level 3 fair value measurements: Balance, December 31, 2022 $ 25,310 Increase in fair value recorded in earnings — Payments (25,310) Balance, September 30, 2023 $ —

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows. Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of September 30, 2023 and December 31, 2022. A fire caused damage to our facility in Annecy, France in June 2016. We were insured for the damages caused by the fire, including business interruption insurance. During the second quarter of 2022, we filed a lawsuit against the insurance company to recover a part of our claim. No gain contingencies have been recognized as our ability to realize those gains remains uncertain. We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $13 million in principal and $5 million to $6 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the amount of the assessment and the timing of our appeal, no liability is recorded as of September 30, 2023.

STOCK REPURCHASE PROGRAM

STOCK REPURCHASE PROGRAM	9 Months Ended
STOCK REPURCHASE PROGRAM	Sep. 30, 2023
Equity [Abstract]
STOCK REPURCHASE PROGRAM	STOCK REPURCHASE PROGRAM On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. During the three and nine months ended September 30, 2023, we repurchased approximately 66 thousand shares for $8.3 million and 318 thousand shares for $37.3 million, respectively. During the three and nine months ended September 30, 2022, we repurchased approximately 181 thousand shares for $19.2 million and 669 thousand shares for $72.3 million, respectively. As of September 30, 2023, there was $70.9 million of authorized share repurchases remaining under the existing authorization.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATIONWe issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs will vest solely based on our return on invested capital ("ROIC"). Award share payouts depend on the extent to which the ROIC performance goal has been achieved, but the final payout is adjusted by a total shareholder return ("TSR") modifier. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest on or around the first anniversary of the date of grant. The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Nine Months Ended September 30, 2023 (1) 2022 Fair value per stock award $ 116.17 $ 141.95 Grant date stock price $ 111.38 $ 114.52 Assumptions: Aptar's stock price expected volatility 20.00 % 20.20 % Expected average volatility of peer companies 39.70 % 41.70 % Correlation assumption 33.30 % 41.20 % Risk-free interest rate 3.83 % 2.04 % Dividend yield assumption 1.36 % 1.33 % ________________________________________________ (1) The 2023 award inputs and assumptions are related to PSU-ROIC awards with a TSR modifier. A summary of RSU activity as of September 30, 2023 and changes during the nine month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2023 426,361 $ 111.60 610,871 $ 118.77 Granted 121,848 110.30 151,415 115.69 Vested (181,248) 104.29 (99,878) 89.33 Forfeited (11,488) 108.05 (133,905) 93.61 Nonvested at September 30, 2023 355,473 $ 115.08 528,503 $ 129.82 Included in the time-based RSU activity for the nine months ended September 30, 2023 are 10,614 units granted to non-employee directors and 10,589 units vested related to non-employee directors. Nine Months Ended September 30, 2023 2022 Compensation expense $ 32,209 $ 31,925 Fair value of units vested 27,662 20,663 Intrinsic value of units vested 32,319 22,329 The actual tax benefit realized for the tax deduction from RSUs was approximately $5.6 million and $6.2 million in the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $53.0 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 1.9 years. Historically we issued stock options to our employees and non-employee directors. We did not issue stock options between 2019 and 2022. Stock options were awarded in the first quarter of 2023 with the exercise price equal to the market price on the date of grant based on the Black-Scholes model and generally vest over three years and expire 10 years after grant. The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all others employees, respectively, during the first nine months of 2023. Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Nine Months Ended September 30, 2023 Dividend Yield 1.41 % Expected Stock Price Volatility 16.55 % Risk-free Interest Rate 3.57 % Expected Life of Option (years) 7 A summary of option activity under our stock plans during the nine months ended September 30, 2023 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2023 2,623,944 $ 73.34 51,700 $ 63.91 Granted 314,833 116.20 — — Exercised (545,104) 69.30 (32,700) 62.36 Forfeited or expired (4,130) 83.84 — — Outstanding at September 30, 2023 2,389,543 $ 79.89 19,000 $ 66.59 Exercisable at September 30, 2023 2,075,973 $ 74.40 19,000 $ 66.59 Weighted-Average Remaining Contractual Term (Years): Outstanding at September 30, 2023 3.7 0.6 Exercisable at September 30, 2023 2.8 0.6 Aggregate Intrinsic Value: Outstanding at September 30, 2023 $ 108,471 $ 1,115 Exercisable at September 30, 2023 $ 105,629 $ 1,115 Intrinsic Value of Options Exercised During the Nine Months Ended: September 30, 2023 $ 27,392 $ 1,978 September 30, 2022 $ 13,618 $ — Nine Months Ended September 30, 2023 Compensation expense (included in SG&A) $ 3,561 Compensation expense (included in Cost of sales) 314 Compensation expense, Total $ 3,875 Compensation expense, net of tax 3,875 The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises for the nine months ended September 30, 2023 and 2022 was approximately $39.7 million and $18.4 million, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $6.8 million and $2.8 million in the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, there was $3.1 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 2.2 years.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
EARNINGS PER SHARE	Sep. 30, 2023
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 was as follows: Three Months Ended September 30, 2023 September 30, 2022 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 84,296 $ 84,296 $ 54,244 $ 54,244 Average equivalent shares Shares of common stock 65,707 65,707 65,322 65,322 Effect of dilutive stock-based compensation Stock options 874 — 884 — Restricted stock 454 — 375 — Total average equivalent shares 67,035 65,707 66,581 65,322 Net income per share $ 1.26 $ 1.28 $ 0.81 $ 0.83 Nine Months Ended September 30, 2023 September 30, 2022 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 222,132 $ 222,132 $ 180,292 $ 180,292 Average equivalent shares Shares of common stock 65,550 65,550 65,446 65,446 Effect of dilutive stock-based compensation Stock options 886 — 1,034 — Restricted stock 429 — 345 — Total average equivalent shares 66,865 65,550 66,825 65,446 Net income per share $ 3.32 $ 3.39 $ 2.70 $ 2.75

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
SEGMENT INFORMATION	Sep. 30, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION During the year ended December 31, 2022, our organizational structure consisted of three market-focused business segments: Pharma, Beauty+Home and Food+Beverage. Effective January 1, 2023, we realigned two of our segments, allowing us to better serve our customers and positioning us for long-term profitable growth. We continue to have three reporting segments; Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets. We combined all of our closures operations into a single segment - Aptar Closures. The Aptar Closures business serves multiple markets, including food, beverage, personal care, home care, beauty and healthcare. Closures that were developed in Beauty + Home moved to Aptar Closures together with the operations of legacy Food + Beverage. Aptar's food protection business and our elastomeric flow-control technology business continue to report through the Aptar Closures segment. At the same time, we have simplified and focused our Beauty + Home segment to better leverage our complex spray and dispensing solutions for prestige and premium brands in the beauty and personal care markets. For many of our customers, personal care products are considered part of "beauty" and so we renamed this segment, simply, Aptar Beauty. The segment realignment had no impact on our consolidated statements of income, balance sheets, and cash flows. Segment financial information for the prior periods has been recast to conform to the current presentation. The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2022. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Financial information regarding our reporting segments is shown below: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Total Sales: Aptar Pharma $ 389,423 $ 345,079 $ 1,136,544 $ 1,037,120 Aptar Beauty 330,467 308,353 1,002,209 947,515 Aptar Closures 181,562 192,706 539,472 577,940 Total Sales $ 901,452 $ 846,138 $ 2,678,225 $ 2,562,575 Less: Intersegment Sales: Aptar Pharma $ 235 $ 1,682 $ 610 $ 11,030 Aptar Beauty 6,487 5,307 22,253 17,722 Aptar Closures 1,733 2,289 6,392 7,488 Total Intersegment Sales $ 8,455 $ 9,278 $ 29,255 $ 36,240 Net Sales: Aptar Pharma $ 389,188 $ 343,397 $ 1,135,934 $ 1,026,090 Aptar Beauty 323,980 303,046 979,956 929,793 Aptar Closures 179,829 190,417 533,080 570,452 Net Sales $ 892,997 $ 836,860 $ 2,648,970 $ 2,526,335 Adjusted EBITDA (1): Aptar Pharma $ 136,344 $ 107,235 $ 371,508 $ 333,793 Aptar Beauty 41,070 36,563 121,375 112,343 Aptar Closures 27,607 23,483 81,387 69,020 Corporate & Other, unallocated (11,659) (13,537) (45,996) (45,170) Acquisition-related costs (2) — (231) (255) (231) Restructuring Initiatives (3) (6,161) (2,270) (19,628) (2,989) Net unrealized investment (loss) gain (4) (5,428) 277 (2,349) (2,297) Depreciation and amortization (62,686) (57,601) (184,212) (174,818) Interest Expense (9,984) (9,756) (29,900) (30,668) Interest Income 946 752 2,266 2,029 Income before Income Taxes $ 110,049 $ 84,915 $ 294,196 $ 261,012 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 – Acquisitions for further details). (3) Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2023 and 2022 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restructuring Initiatives by Plan: Optimization initiative $ 6,586 $ 2,254 $ 20,069 $ 2,254 Prior year initiatives (425) 16 (441) 735 Total Restructuring Initiatives $ 6,161 $ 2,270 $ 19,628 $ 2,989 Restructuring Initiatives by Segment: Aptar Pharma $ 92 $ — $ 1,657 $ — Aptar Beauty 2,880 2,240 12,650 2,774 Aptar Closures 3,098 30 4,060 215 Corporate & Other 91 — 1,261 — Total Restructuring Initiatives $ 6,161 $ 2,270 $ 19,628 $ 2,989 (4) Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).

ACQUISITIONS

ACQUISITIONS	9 Months Ended
ACQUISITIONS	Sep. 30, 2023
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	ACQUISITIONS Business Combinations On August 1, 2023, we paid the remaining $5.2 million purchase price in relation to the 2021 Hengyu acquisition. No further liability remains outstanding for this acquisition. On March 1, 2023, we completed the acquisition of all the outstanding capital stock of iD SCENT. Located in Lyon, France, iD SCENT is an expert producer of paper fragrance sampling solutions that present multiple sustainability features. The purchase price was approximately $9.4 million (net of $1.4 million cash acquired) and was funded with cash on hand. The results of iD SCENT have been included in the consolidated financial statements within our Aptar Beauty segment since the date of acquisition. Also on March 1, 2023, we completed the acquisition of 80% of the equity interest of Gulf Closures W.L.L. ( "Gulf Closures"). Gulf Closures, located in Bahrain, is a closure manufacturer for beverage products. The purchase price for 80% ownership was approximately $1.5 million (net of $1.2 million cash acquired) and was funded with cash on hand. This values the full company equity at approximately $3.3 million and implies a non-controlling interest valued at approximately $0.7 million as of the acquisition date. The results of Gulf Closures have been included in the consolidated financial statements within our Aptar Closures segment since the date of acquisition. On August 31, 2022, we completed the acquisition of all the outstanding capital stock of Metaphase Design Group Inc. ("Metaphase"). Metaphase, located in St. Louis, Missouri, is a leading expert in ergonomic and industrial design of handheld devices including medical devices. The purchase price was approximately $5.1 million (net of $0.1 million cash acquired) and was funded with cash on hand. As of the acquisition date, $1.0 million was held in restricted cash for an indemnity escrow. The results of Metaphase have been included in the consolidated financial statements within our Aptar Pharma segment since the date of acquisition.

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	9 Months Ended
INVESTMENT IN EQUITY SECURITIES	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENT IN EQUITY SECURITIES	INVESTMENT IN EQUITY SECURITIES Our investment in equity securities consisted of the following: September 30, December 31, Equity Method Investments: BTY $ 31,665 $ 31,490 Sonmol 4,621 4,997 Desotec GmbH 859 863 Other Investments: PureCycle 1,532 5,297 YAT 5,204 5,508 Loop 2,894 2,894 Others 1,247 1,259 $ 48,022 $ 52,308 Equity Method Investments BTY On January 1, 2020, we acquired 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the nine months ended September 30, 2023 and September 30, 2022, Aptar had purchases of $10.7 million and $7.2 million, respectively, from BTY. As of September 30, 2023 and December 31, 2022, approximately $2.1 million and $1.5 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets. Sonmol On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control. Desotec GmbH During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and closures markets. Other Investments In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company. In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In November 2020, we increased the value of the PureCycle investment by $3.1 million based on observable price changes. In March 2021, PureCycle was purchased by a special purpose acquisition company and was subsequently listed on Nasdaq under the ticker PCT. At that time, our investment in PureCycle was converted into shares of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain March 2022 107,600 $ 1,088 $ 841 August 2022 50,000 $ 511 $ 372 July 2023 248,859 $ 2,659 $ 1,968 August 2023 261,590 $ 2,945 $ 2,220 For the three and nine months ended September 30, 2023 and 2022, we recorded the following net investment gain or loss on our investment in PureCycle: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net investment (loss) gain $ (1,240) $ 649 $ 1,839 $ (1,084) On July 7, 2021, we investe d approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company. There were no indications of impairment noted in the nine months ended September 30, 2023 related to these investments. In March 2022, we recorded a $1.5 million expected credit loss reserve against the outstanding note receivable from one of our venture investments (Kali Care) as a result of a proposed sale of such business.

RESTRUCTURING INITIATIVES

RESTRUCTURING INITIATIVES	9 Months Ended
RESTRUCTURING INITIATIVES	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
RESTRUCTURING INITIATIVES	RESTRUCTURING INITIATIVES During the third quarter of 2022, we began an initiative to better leverage our fixed cost base through growth and cost reduction measures. For the three and nine months ended September 30, 2023, we recognized $6.6 million and $20.1 million of restructuring costs related to this initiative, respectively. For the three months ended September 30, 2022, we recognized $2.3 million of restructuring costs related to this initiative. The cumulative expense incurred as of September 30, 2023 was $26.3 million. As of September 30, 2023, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at 12/31/2022 Net Charges for the Nine Months Ended 9/30/2023 Cash Paid Interest and Ending Reserve at 9/30/2023 Employee severance $ 4,993 $ 15,833 $ (8,605) $ (105) $ 12,116 Professional fees and other costs — 4,236 (3,991) 8 253 Totals $ 4,993 $ 20,069 $ (12,596) $ (97) $ 12,369

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 84,296	$ 54,244	$ 222,132	$ 180,292

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation. In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2022 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2022. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.
ADOPTION OF RECENT ACCOUNTING STANDARDS	ADOPTION OF RECENT ACCOUNTING STANDARDS Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification. In September 2022, the FASB issued ASU 2022-04, Liabilities-Supplier Finance Programs (Topic 405), which enhances the transparency of supplier finance programs and requires certain disclosures for a buyer in a supplier finance program. The requirements are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 13, 2023. Early adoption is permitted. We adopted this guidance in the fourth quarter of 2022. In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from LIBOR to SOFR in our revolving credit facility. Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.
INCOME TAXES	INCOME TAXES We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create timing differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany, the pre-2023 earnings in Suzhou, China and the pre-2020 earnings in Italy, Switzerland and Colombia. The change in the Suzhou, China assertion was made in the current quarter. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation on a current or deferred basis. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service and other tax authorities and government bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with our expectations, we could be required to adjust our provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.
ASSETS HELD FOR SALE	ASSETS HELD FOR SALE Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale.
SUPPLY CHAIN FINANCE PROGRAM	SUPPLY CHAIN FINANCE PROGRAM We facilitate a supply chain finance program ("SCF") across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions. All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2023, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $37.3 million. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
REVENUE (Tables)	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of revenue by segment by geographic area	Revenue by segment and geography based on shipped from locations for the three and nine months ended September 30, 2023 and 2022 was as follows: For the Three Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 252,174 $ 106,804 $ 11,118 $ 19,092 $ 389,188 Aptar Beauty 203,599 58,181 39,963 22,237 323,980 Aptar Closures 53,431 89,795 21,956 14,647 179,829 Total $ 509,204 $ 254,780 $ 73,037 $ 55,976 $ 892,997 For the Three Months Ended September 30, 2022 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 212,751 $ 105,542 $ 6,309 $ 18,795 $ 343,397 Aptar Beauty 169,936 75,070 35,195 22,845 303,046 Aptar Closures 54,146 99,198 21,777 15,296 190,417 Total $ 436,833 $ 279,810 $ 63,281 $ 56,936 $ 836,860 For the Nine Months Ended September 30, 2023 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 733,749 $ 309,946 $ 30,699 $ 61,540 $ 1,135,934 Aptar Beauty 629,168 175,942 113,282 61,564 979,956 Aptar Closures 167,836 261,903 63,128 40,213 533,080 Total $ 1,530,753 $ 747,791 $ 207,109 $ 163,317 $ 2,648,970 For the Nine Months Ended September 30, 2022 Segment Europe Domestic Latin Asia Total Aptar Pharma $ 632,876 $ 320,297 $ 20,503 $ 52,414 $ 1,026,090 Aptar Beauty 540,629 224,269 97,337 67,558 929,793 Aptar Closures 163,424 304,051 62,327 40,650 570,452 Total $ 1,336,929 $ 848,617 $ 180,167 $ 160,622 $ 2,526,335
Schedule of opening and closing balances of contract assets and contract liabilities	The opening and closing balances of our contract asset and contract liabilities were as follows: Balance as of December 31, 2022 Balance as of September 30, 2023 Increase/ Contract asset (current) $ 16,736 $ 19,768 $ 3,032 Contract liability (current) 80,241 73,282 (6,959) Contract liability (long-term) 25,361 32,818 7,457

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
INVENTORIES (Tables)	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of inventories, by component	Inventories, by component net of reserves, consisted of: September 30, December 31, Raw materials $ 145,742 $ 159,041 Work in process 173,453 153,592 Finished goods 171,677 174,173 Total $ 490,872 $ 486,806

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of changes in the carrying amount of goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2023 by reporting segment were as follows: Aptar Aptar Aptar Closures Total Balance as of December 31, 2022 $ 498,742 $ 319,011 $ 127,879 $ 945,632 Reclassification due to segment change — (39,472) 39,472 — Acquisitions — 3,655 114 3,769 Foreign currency exchange effects (5,191) (1,025) (148) (6,364) Balance as of September 30, 2023 $ 493,551 $ 282,169 $ 167,317 $ 943,037
Summary of amortized intangible assets	The table below shows a summary of intangible assets as of September 30, 2023 and December 31, 2022. September 30, 2023 December 31, 2022 Weighted Average Amortization Period (Years) Gross Accumulated Net Gross Accumulated Net Amortized intangible assets: Patents 9.8 $ 7,181 $ (1,617) $ 5,564 $ 8,044 $ (1,968) $ 6,076 Acquired technology 11.4 136,860 (65,378) 71,482 135,191 (56,628) 78,563 Customer relationships 13.5 304,726 (116,570) 188,156 305,994 (99,130) 206,864 Trademarks and trade names 7.5 44,140 (32,555) 11,585 43,998 (28,190) 15,808 License agreements and other 31.4 16,910 (6,466) 10,444 15,425 (6,992) 8,433 Total intangible assets 13.3 $ 509,817 $ (222,586) $ 287,231 $ 508,652 $ (192,908) $ 315,744
Schedule of future estimated amortization expense	future estimated amortization expense for the years ending December 31 is as follows: 2023 $ 11,473 (remaining estimated amortization for 2023) 2024 41,267 2025 39,565 2026 37,287 2027 26,026 Thereafter 131,613

DEBT (Tables)

DEBT (Tables)	9 Months Ended
DEBT (Tables)	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of short-term debt	At September 30, 2023 and December 31, 2022, our notes payable, revolving credit facility and overdrafts consisted of the following: September 30, December 31, Revolving credit facility 4.73% to 6.18% $ 123,790 $ — Overdrafts 4.64% to 4.71% 713 3,810 $ 124,503 $ 3,810
Schedule of long-term obligations	At September 30, 2023 and December 31, 2022, our long-term obligations consisted of the following: September 30, 2023 December 31, 2022 Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031 $ 15,005 $ 29,167 Senior unsecured notes 1.0%, due in 2023 — 106,995 Senior unsecured notes 3.4%, due in 2024 50,000 50,000 Senior unsecured notes 3.5%, due in 2024 100,000 100,000 Senior unsecured notes 1.2%, due in 2024 211,440 213,990 Senior unsecured notes 3.6%, due in 2025 125,000 125,000 Senior unsecured notes 3.6%, due in 2026 125,000 125,000 Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million 399,128 399,050 Finance Lease Liabilities 24,867 26,934 Unamortized debt issuance costs (3,997) (4,558) $ 1,046,443 $ 1,171,578 Current maturities of long-term obligations (366,378) (118,981) Total long-term obligations $ 680,065 $ 1,052,597
Schedule of maturities of long-term debt	The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are: Year One $ 363,408 Year Two 6,368 Year Three 256,200 Year Four 315 Year Five 72 Thereafter 399,210
Schedule of covenants on revolving credit facility and corporate long-term obligations	Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including: Requirement Level at September 30, 2023 Consolidated Leverage Ratio (1) Maximum of 3.50 to 1.00 1.61 to 1.00 Consolidated Interest Coverage Ratio (1) Minimum of 3.00 to 1.00 16.19 to 1.00 ________________________________________

LEASES (Tables)

LEASES (Tables)	9 Months Ended
LEASES (Tables)	Sep. 30, 2023
Leases [Abstract]
Schedule of components of lease expense	The components of lease expense for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Operating lease cost $ 5,150 $ 4,870 $ 15,841 $ 15,605 Finance lease cost: Amortization of right-of-use assets $ 908 $ 1,050 $ 2,686 $ 3,307 Interest on lease liabilities 289 307 883 947 Total finance lease cost $ 1,197 $ 1,357 $ 3,569 $ 4,254 Short-term lease and variable lease costs $ 5,774 $ 4,226 $ 15,883 $ 11,437
Schedule of supplemental cash flow information related to leases	Supplemental cash flow information related to leases was as follows: Nine Months Ended September 30, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 15,993 $ 15,001 Operating cash flows from finance leases 883 941 Financing cash flows from finance leases 2,377 2,749 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 7,764 $ 13,146 Finance leases 401 919

RETIREMENT AND DEFERRED COMPE_2

RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	9 Months Ended
RETIREMENT AND DEFERRED COMPENSATION PLANS (Tables)	Sep. 30, 2023
Retirement Benefits [Abstract]
Components of net periodic benefit cost	Components of Net Periodic Benefit Cost: Domestic Plans Foreign Plans Three Months Ended September 30, 2023 2022 2023 2022 Service cost $ 2,409 $ 3,948 $ 1,487 $ 1,775 Interest cost 2,158 1,742 915 330 Expected return on plan assets (3,094) (3,228) (589) (653) Amortization of net loss — 1,668 230 403 Amortization of prior service cost — — 45 35 Net periodic benefit cost $ 1,473 $ 4,130 $ 2,088 $ 1,890 Domestic Plans Foreign Plans Nine Months Ended September 30, 2023 2022 2023 2022 Service cost $ 7,228 $ 11,838 $ 4,444 $ 5,621 Interest cost 6,473 5,227 2,735 1,045 Expected return on plan assets (9,283) (9,684) (1,758) (2,069) Amortization of net loss — 5,003 687 1,280 Amortization of prior service cost — — 133 106 Net periodic benefit cost $ 4,418 $ 12,384 $ 6,241 $ 5,983

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	9 Months Ended
ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (Tables)	Sep. 30, 2023
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Changes in Accumulated Other Comprehensive (Loss) Income by Component	Changes in Accumulated Other Comprehensive (Loss) Income by Component: Foreign Currency Defined Benefit Pension Plans Derivatives Total Balance - December 31, 2021 $ (249,500) $ (66,486) $ (55) $ (316,041) Other comprehensive (loss) income before reclassifications (182,432) (719) 3,617 (179,534) Amounts reclassified from accumulated other comprehensive income (loss) — 4,781 46 4,827 Net current-period other comprehensive (loss) income (182,432) 4,062 3,663 (174,707) Balance - September 30, 2022 $ (431,932) $ (62,424) $ 3,608 $ (490,748) Balance - December 31, 2022 $ (328,740) $ (5,951) $ (6,675) $ (341,366) Other comprehensive income (loss) before reclassifications (28,294) 63 (2,424) (30,655) Amounts reclassified from accumulated other comprehensive income — 581 — 581 Net current-period other comprehensive income (loss) (28,294) 644 (2,424) (30,074) Balance - September 30, 2023 $ (357,034) $ (5,307) $ (9,099) $ (371,440)
Reclassifications Out of Accumulated Other Comprehensive (Loss) Income	Reclassifications Out of Accumulated Other Comprehensive (Loss) Income: Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Three Months Ended September 30, 2023 2022 Defined Benefit Pension Plans Amortization of net loss $ 230 $ 2,071 (1) Amortization of prior service cost 45 35 (1) 275 2,106 Total before tax (81) (530) Tax impact $ 194 $ 1,576 Net of tax Derivatives Changes in cross currency swap: interest component $ — $ (33) Interest Expense Changes in cross currency swap: foreign exchange component — 4,843 Miscellaneous, net $ — $ 4,810 Net of tax Total reclassifications for the period $ 194 $ 6,386 Details about Accumulated Other Amount Reclassified from Accumulated Other Comprehensive Income Affected Line in the Statement Nine Months Ended September 30, 2023 2022 Defined Benefit Pension Plans Amortization of net loss $ 687 $ 6,283 (1) Amortization of prior service cost 133 106 (1) 820 6,389 Total before tax (239) (1,608) Tax impact $ 581 $ 4,781 Net of tax Derivatives Changes in cross currency swap: interest component $ — $ (171) Interest Expense Changes in cross currency swap: foreign exchange component — 217 Miscellaneous, net $ — $ 46 Net of tax Total reclassifications for the period $ 581 $ 4,827 ______________________________________________ (1) These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	9 Months Ended
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of fair value of derivative instruments in the consolidated balance sheets	Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 September 30, 2023 December 31, 2022 Balance Sheet Location Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivatives Designated as Hedging Instruments Derivatives not Designated as Hedging Instruments Derivative Assets Foreign Exchange Contracts Prepaid and other $ — $ 377 $ — $ 1,107 $ — $ 377 $ — $ 1,107 Derivative Liabilities Foreign Exchange Contracts Accounts payable, accrued and other liabilities $ — $ 305 $ — $ 269 Cross Currency Swap Contract (1) Accounts payable, accrued and other liabilities 12,049 — 8,840 — $ 12,049 $ 305 $ 8,840 $ 269 __________________________ (1) This cross currency swap agreement is composed of both an interest component and a foreign exchange component.
Schedule of effect of cash flow hedge accounting on accumulated other comprehensive income (loss)	The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, 2023 and 2022 Derivatives Designated as Hedging Instruments Amount of Gain (Loss) Location of (Loss) Amount of Gain (Loss) Total Amount of Affected Income Statement Line Item 2023 2022 2023 2022 Cross currency swap agreement: Interest component $ — $ (30) Interest expense $ — $ 33 $ (9,984) Foreign exchange component 2,707 (1,238) Miscellaneous, net — (4,843) 3 $ 2,707 $ (1,268) $ — $ (4,810) The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2023 and 2022 Derivatives Designated as Hedging Instruments Amount of Gain Location of Gain Recognized Amount of Gain Total Amount of Affected Income Statement Line Item 2023 2022 2023 2022 Cross currency swap agreement: Interest component $ — $ 229 Interest expense $ — $ 171 $ (29,900) Foreign exchange component (2,424) 3,388 Miscellaneous, net — (217) (1,341) $ (2,424) $ 3,617 $ — $ (46)
Schedule of effect of derivatives not designated as hedging instruments on the consolidated statements of income	The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2023 and 2022 Derivatives Not Designated Location of (Loss) Gain Recognized Amount of (Loss) Gain 2023 2022 Foreign Exchange Contracts Other (Expense) Income: $ 44 $ (853) $ 44 $ (853) The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2023 and 2022 Derivatives Not Designated Location of Loss Recognized Amount of Loss 2023 2022 Foreign Exchange Contracts Other (Expense) Income: $ (756) $ (962) $ (756) $ (962)
Schedule of offsetting derivative assets and liabilities	Gross Amounts Offset in the Statement of Financial Position Net Amounts Presented in the Statement of Financial Position Gross Amounts not Offset in the Statement of Financial Position Gross Amount Financial Instruments Cash Collateral Received Net Amount September 30, 2023 Derivative Assets $ 377 — $ 377 — — $ 377 Total Assets $ 377 — $ 377 — — $ 377 Derivative Liabilities $ 12,354 — $ 12,354 — — $ 12,354 Total Liabilities $ 12,354 — $ 12,354 — — $ 12,354 December 31, 2022 Derivative Assets $ 1,107 — $ 1,107 — — $ 1,107 Total Assets $ 1,107 — $ 1,107 — — $ 1,107 Derivative Liabilities $ 9,109 — $ 9,109 — — $ 9,109 Total Liabilities $ 9,109 — $ 9,109 — — $ 9,109

FAIR VALUE (Tables)

FAIR VALUE (Tables)	9 Months Ended
FAIR VALUE (Tables)	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of fair values of financial assets and liabilities	As of September 30, 2023, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 1,532 $ 1,532 $ — $ — Foreign exchange contracts (2) 377 — 377 — Convertible notes 5,650 — — 5,650 Total assets at fair value $ 7,559 $ 1,532 $ 377 $ 5,650 Liabilities Foreign exchange contracts (2) $ 305 $ — $ 305 $ — Cross currency swap contract (2) 12,049 — 12,049 — Total liabilities at fair value $ 12,354 $ — $ 12,354 $ — As of December 31, 2022, the fair values of our financial assets and liabilities were categorized as follows: Total Level 1 Level 2 Level 3 Assets Investment in equity securities (1) $ 5,297 $ 5,297 $ — $ — Foreign exchange contracts (2) 1,107 — 1,107 — Convertible note 5,650 — — 5,650 Total assets at fair value $ 12,054 $ 5,297 $ 1,107 $ 5,650 Liabilities Foreign exchange contracts (2) $ 269 $ — $ 269 $ — Cross currency swap contract (2) 8,840 — 8,840 — Contingent consideration obligation 25,310 — — 25,310 Total liabilities at fair value $ 34,419 $ — $ 9,109 $ 25,310 ________________________________________________ (1) Investment in PureCycle Technologies ("PCT" or "PureCycle"). See Note 18 – Investment in Equity Securities for discussion of this investment. (2) Market approach valuation technique based on observable market transactions of spot and forward rates.
Schedule of contingent consideration arrangements, fair value	We consider these obligations a Level 3 liability and estimated the aggregate fair value for these contingent consideration arrangements as follows: September 30, 2023 December 31, 2022 Fusion Acquisition $ — $ 25,310 Noble Acquisition — — $ — $ 25,310
Summary of changes in Level 3 fair value measurements	The following table provides a summary of changes in our Level 3 fair value measurements: Balance, December 31, 2022 $ 25,310 Increase in fair value recorded in earnings — Payments (25,310) Balance, September 30, 2023 $ —

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Weighted-average assumptions used to estimate fair value of restricted stock units	Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement. Nine Months Ended September 30, 2023 (1) 2022 Fair value per stock award $ 116.17 $ 141.95 Grant date stock price $ 111.38 $ 114.52 Assumptions: Aptar's stock price expected volatility 20.00 % 20.20 % Expected average volatility of peer companies 39.70 % 41.70 % Correlation assumption 33.30 % 41.20 % Risk-free interest rate 3.83 % 2.04 % Dividend yield assumption 1.36 % 1.33 % ________________________________________________ (1) The 2023 award inputs and assumptions are related to PSU-ROIC awards with a TSR modifier.
Summary of restricted stock unit activity	A summary of RSU activity as of September 30, 2023 and changes during the nine month period then ended is presented below: Time-Based RSUs Performance-Based RSUs Units Weighted Average Units Weighted Average Nonvested at January 1, 2023 426,361 $ 111.60 610,871 $ 118.77 Granted 121,848 110.30 151,415 115.69 Vested (181,248) 104.29 (99,878) 89.33 Forfeited (11,488) 108.05 (133,905) 93.61 Nonvested at September 30, 2023 355,473 $ 115.08 528,503 $ 129.82
Schedule of compensation expense, fair value, and intrinsic value related to RSU's	Nine Months Ended September 30, 2023 2022 Compensation expense $ 32,209 $ 31,925 Fair value of units vested 27,662 20,663 Intrinsic value of units vested 32,319 22,329
Schedule of share-based payment award, stock options, valuation assumptions	These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: Stock Award Plans: Nine Months Ended September 30, 2023 Dividend Yield 1.41 % Expected Stock Price Volatility 16.55 % Risk-free Interest Rate 3.57 % Expected Life of Option (years) 7
Summary of option activity	A summary of option activity under our stock plans during the nine months ended September 30, 2023 is presented below: Stock Awards Plans Director Stock Option Plans Options Weighted Average Options Weighted Average Outstanding, January 1, 2023 2,623,944 $ 73.34 51,700 $ 63.91 Granted 314,833 116.20 — — Exercised (545,104) 69.30 (32,700) 62.36 Forfeited or expired (4,130) 83.84 — — Outstanding at September 30, 2023 2,389,543 $ 79.89 19,000 $ 66.59 Exercisable at September 30, 2023 2,075,973 $ 74.40 19,000 $ 66.59 Weighted-Average Remaining Contractual Term (Years): Outstanding at September 30, 2023 3.7 0.6 Exercisable at September 30, 2023 2.8 0.6 Aggregate Intrinsic Value: Outstanding at September 30, 2023 $ 108,471 $ 1,115 Exercisable at September 30, 2023 $ 105,629 $ 1,115 Intrinsic Value of Options Exercised During the Nine Months Ended: September 30, 2023 $ 27,392 $ 1,978 September 30, 2022 $ 13,618 $ —
Schedule of compensation expense, and fair value related to options	Nine Months Ended September 30, 2023 Compensation expense (included in SG&A) $ 3,561 Compensation expense (included in Cost of sales) 314 Compensation expense, Total $ 3,875 Compensation expense, net of tax 3,875

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
EARNINGS PER SHARE (Tables)	Sep. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Earnings Per Share	The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2023 and 2022 was as follows: Three Months Ended September 30, 2023 September 30, 2022 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 84,296 $ 84,296 $ 54,244 $ 54,244 Average equivalent shares Shares of common stock 65,707 65,707 65,322 65,322 Effect of dilutive stock-based compensation Stock options 874 — 884 — Restricted stock 454 — 375 — Total average equivalent shares 67,035 65,707 66,581 65,322 Net income per share $ 1.26 $ 1.28 $ 0.81 $ 0.83 Nine Months Ended September 30, 2023 September 30, 2022 Diluted Basic Diluted Basic Consolidated operations Income available to common stockholders $ 222,132 $ 222,132 $ 180,292 $ 180,292 Average equivalent shares Shares of common stock 65,550 65,550 65,446 65,446 Effect of dilutive stock-based compensation Stock options 886 — 1,034 — Restricted stock 429 — 345 — Total average equivalent shares 66,865 65,550 66,825 65,446 Net income per share $ 3.32 $ 3.39 $ 2.70 $ 2.75

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
SEGMENT INFORMATION (Tables)	Sep. 30, 2023
Segment Reporting [Abstract]
Financial information regarding the company's reportable segments	Financial information regarding our reporting segments is shown below: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Total Sales: Aptar Pharma $ 389,423 $ 345,079 $ 1,136,544 $ 1,037,120 Aptar Beauty 330,467 308,353 1,002,209 947,515 Aptar Closures 181,562 192,706 539,472 577,940 Total Sales $ 901,452 $ 846,138 $ 2,678,225 $ 2,562,575 Less: Intersegment Sales: Aptar Pharma $ 235 $ 1,682 $ 610 $ 11,030 Aptar Beauty 6,487 5,307 22,253 17,722 Aptar Closures 1,733 2,289 6,392 7,488 Total Intersegment Sales $ 8,455 $ 9,278 $ 29,255 $ 36,240 Net Sales: Aptar Pharma $ 389,188 $ 343,397 $ 1,135,934 $ 1,026,090 Aptar Beauty 323,980 303,046 979,956 929,793 Aptar Closures 179,829 190,417 533,080 570,452 Net Sales $ 892,997 $ 836,860 $ 2,648,970 $ 2,526,335 Adjusted EBITDA (1): Aptar Pharma $ 136,344 $ 107,235 $ 371,508 $ 333,793 Aptar Beauty 41,070 36,563 121,375 112,343 Aptar Closures 27,607 23,483 81,387 69,020 Corporate & Other, unallocated (11,659) (13,537) (45,996) (45,170) Acquisition-related costs (2) — (231) (255) (231) Restructuring Initiatives (3) (6,161) (2,270) (19,628) (2,989) Net unrealized investment (loss) gain (4) (5,428) 277 (2,349) (2,297) Depreciation and amortization (62,686) (57,601) (184,212) (174,818) Interest Expense (9,984) (9,756) (29,900) (30,668) Interest Income 946 752 2,266 2,029 Income before Income Taxes $ 110,049 $ 84,915 $ 294,196 $ 261,012 ________________________________________________ (1) We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. (2) Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 – Acquisitions for further details). (3) Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2023 and 2022 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restructuring Initiatives by Plan: Optimization initiative $ 6,586 $ 2,254 $ 20,069 $ 2,254 Prior year initiatives (425) 16 (441) 735 Total Restructuring Initiatives $ 6,161 $ 2,270 $ 19,628 $ 2,989 Restructuring Initiatives by Segment: Aptar Pharma $ 92 $ — $ 1,657 $ — Aptar Beauty 2,880 2,240 12,650 2,774 Aptar Closures 3,098 30 4,060 215 Corporate & Other 91 — 1,261 — Total Restructuring Initiatives $ 6,161 $ 2,270 $ 19,628 $ 2,989 (4) Net unrealized investment gain (loss) represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).
Restructuring Initiatives	Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2023 and 2022 as follows (see Note 19 – Restructuring Initiatives for further details): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restructuring Initiatives by Plan: Optimization initiative $ 6,586 $ 2,254 $ 20,069 $ 2,254 Prior year initiatives (425) 16 (441) 735 Total Restructuring Initiatives $ 6,161 $ 2,270 $ 19,628 $ 2,989 Restructuring Initiatives by Segment: Aptar Pharma $ 92 $ — $ 1,657 $ — Aptar Beauty 2,880 2,240 12,650 2,774 Aptar Closures 3,098 30 4,060 215 Corporate & Other 91 — 1,261 — Total Restructuring Initiatives $ 6,161 $ 2,270 $ 19,628 $ 2,989

INVESTMENT IN EQUITY SECURITI_2

INVESTMENT IN EQUITY SECURITIES (Tables)	9 Months Ended
INVESTMENT IN EQUITY SECURITIES (Tables)	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of investments in equity securities	Our investment in equity securities consisted of the following: September 30, December 31, Equity Method Investments: BTY $ 31,665 $ 31,490 Sonmol 4,621 4,997 Desotec GmbH 859 863 Other Investments: PureCycle 1,532 5,297 YAT 5,204 5,508 Loop 2,894 2,894 Others 1,247 1,259 $ 48,022 $ 52,308
Schedule of investment company, financial highlights	We have sold the following PCT shares related to the PureCycle investment: Shares Sold Proceeds Realized Gain March 2022 107,600 $ 1,088 $ 841 August 2022 50,000 $ 511 $ 372 July 2023 248,859 $ 2,659 $ 1,968 August 2023 261,590 $ 2,945 $ 2,220
Schedule of other nonoperating income (expense)	For the three and nine months ended September 30, 2023 and 2022, we recorded the following net investment gain or loss on our investment in PureCycle: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net investment (loss) gain $ (1,240) $ 649 $ 1,839 $ (1,084)

RESTRUCTURING INITIATIVES (Tabl

RESTRUCTURING INITIATIVES (Tables)	9 Months Ended
RESTRUCTURING INITIATIVES (Tables)	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Schedule of restructuring reserve by type of cost	As of September 30, 2023, we have recorded the following activity associated with our optimization initiative: Beginning Reserve at 12/31/2022 Net Charges for the Nine Months Ended 9/30/2023 Cash Paid Interest and Ending Reserve at 9/30/2023 Employee severance $ 4,993 $ 15,833 $ (8,605) $ (105) $ 12,116 Professional fees and other costs — 4,236 (3,991) 8 253 Totals $ 4,993 $ 20,069 $ (12,596) $ (97) $ 12,369

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($) building	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($) building
Product Information [Line Items]
Assets held-for-sale			$ 0.7
Number of buildings held before sale of 2 buildings \| building			3
Number of buildings sold \| building	2
Gain on sale of buildings	$ 0.8
Supplier finance program obligation, current	$ 37.3	$ 37.3
Minimum
Product Information [Line Items]
Supplier finance program payment terms		60 days
Maximum
Product Information [Line Items]
Supplier finance program payment terms		120 days

REVENUE - Revenue by Geographic

REVENUE - Revenue by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
REVENUE
Net revenue	$ 892,997	$ 836,860	$ 2,648,970	$ 2,526,335
Aptar Pharma
REVENUE
Net revenue	389,188	343,397	1,135,934	1,026,090
Aptar Beauty
REVENUE
Net revenue	323,980	303,046	979,956	929,793
Aptar Closures
REVENUE
Net revenue	179,829	190,417	533,080	570,452
Europe
REVENUE
Net revenue	509,204	436,833	1,530,753	1,336,929
Europe \| Aptar Pharma
REVENUE
Net revenue	252,174	212,751	733,749	632,876
Europe \| Aptar Beauty
REVENUE
Net revenue	203,599	169,936	629,168	540,629
Europe \| Aptar Closures
REVENUE
Net revenue	53,431	54,146	167,836	163,424
Domestic
REVENUE
Net revenue	254,780	279,810	747,791	848,617
Domestic \| Aptar Pharma
REVENUE
Net revenue	106,804	105,542	309,946	320,297
Domestic \| Aptar Beauty
REVENUE
Net revenue	58,181	75,070	175,942	224,269
Domestic \| Aptar Closures
REVENUE
Net revenue	89,795	99,198	261,903	304,051
Latin America
REVENUE
Net revenue	73,037	63,281	207,109	180,167
Latin America \| Aptar Pharma
REVENUE
Net revenue	11,118	6,309	30,699	20,503
Latin America \| Aptar Beauty
REVENUE
Net revenue	39,963	35,195	113,282	97,337
Latin America \| Aptar Closures
REVENUE
Net revenue	21,956	21,777	63,128	62,327
Asia
REVENUE
Net revenue	55,976	56,936	163,317	160,622
Asia \| Aptar Pharma
REVENUE
Net revenue	19,092	18,795	61,540	52,414
Asia \| Aptar Beauty
REVENUE
Net revenue	22,237	22,845	61,564	67,558
Asia \| Aptar Closures
REVENUE
Net revenue	$ 14,647	$ 15,296	$ 40,213	$ 40,650

REVENUE - Contract Assets and C

REVENUE - Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract asset (current)	$ 19,768	$ 16,736
Increase / (decrease) in Contract asset (current)	3,032
Contract liability (current)	73,282	80,241
Increase / (decrease) in Contract liability (current)	(6,959)
Contract liability (long-term)	32,818	$ 25,361
Increase / (decrease) in Contract liability (long-term)	7,457
Revenue recognized previously included in current contract liabilities	106,000
Revenue recognized previously included in current contract liabilities at the beginning of the year	$ 59,400

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventories, by component
Raw materials	$ 145,742	$ 159,041
Work in process	173,453	153,592
Finished goods	171,677	174,173
Total	$ 490,872	$ 486,806

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Changes in the carrying amount of goodwill
Goodwill, beginning balance	$ 945,632
Reclassification due to segment change	0
Acquisitions	3,769
Foreign currency exchange effects	(6,364)
Goodwill, ending balance	943,037
Operating segment \| Aptar Pharma
Changes in the carrying amount of goodwill
Goodwill, beginning balance	498,742
Reclassification due to segment change	0
Acquisitions	0
Foreign currency exchange effects	(5,191)
Goodwill, ending balance	493,551
Operating segment \| Aptar Beauty
Changes in the carrying amount of goodwill
Goodwill, beginning balance	319,011
Reclassification due to segment change	(39,472)
Acquisitions	3,655
Foreign currency exchange effects	(1,025)
Goodwill, ending balance	282,169
Operating segment \| Aptar Closures
Changes in the carrying amount of goodwill
Goodwill, beginning balance	127,879
Reclassification due to segment change	39,472
Acquisitions	114
Foreign currency exchange effects	(148)
Goodwill, ending balance	$ 167,317

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Amortized intangible assets
Gross Carrying Amount	$ 509,817		$ 509,817		$ 508,652
Accumulated Amortization	(222,586)		(222,586)		(192,908)
Net Value	287,231		287,231		315,744
Aggregate amortization expense	$ 11,400	$ 10,678	$ 33,494	$ 32,772
Weighted Average
Amortized intangible assets
Weighted Average Amortization Period (Years)	13 years 3 months 18 days		13 years 3 months 18 days
Patents
Amortized intangible assets
Gross Carrying Amount	$ 7,181		$ 7,181		8,044
Accumulated Amortization	(1,617)		(1,617)		(1,968)
Net Value	$ 5,564		$ 5,564		6,076
Patents \| Weighted Average
Amortized intangible assets
Weighted Average Amortization Period (Years)	9 years 9 months 18 days		9 years 9 months 18 days
Acquired technology
Amortized intangible assets
Gross Carrying Amount	$ 136,860		$ 136,860		135,191
Accumulated Amortization	(65,378)		(65,378)		(56,628)
Net Value	$ 71,482		$ 71,482		78,563
Acquired technology \| Weighted Average
Amortized intangible assets
Weighted Average Amortization Period (Years)	11 years 4 months 24 days		11 years 4 months 24 days
Customer relationships
Amortized intangible assets
Gross Carrying Amount	$ 304,726		$ 304,726		305,994
Accumulated Amortization	(116,570)		(116,570)		(99,130)
Net Value	$ 188,156		$ 188,156		206,864
Customer relationships \| Weighted Average
Amortized intangible assets
Weighted Average Amortization Period (Years)	13 years 6 months		13 years 6 months
Trademarks and trade names
Amortized intangible assets
Gross Carrying Amount	$ 44,140		$ 44,140		43,998
Accumulated Amortization	(32,555)		(32,555)		(28,190)
Net Value	$ 11,585		$ 11,585		15,808
Trademarks and trade names \| Weighted Average
Amortized intangible assets
Weighted Average Amortization Period (Years)	7 years 6 months		7 years 6 months
License agreements and other
Amortized intangible assets
Gross Carrying Amount	$ 16,910		$ 16,910		15,425
Accumulated Amortization	(6,466)		(6,466)		(6,992)
Net Value	$ 10,444		$ 10,444		$ 8,433
License agreements and other \| Weighted Average
Amortized intangible assets
Weighted Average Amortization Period (Years)	31 years 4 months 24 days		31 years 4 months 24 days

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Statement of Financial Position [Abstract]
2023	$ 11,473
2024	41,267
2025	39,565
2026	37,287
2027	26,026
Thereafter	$ 131,613

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate (as a percent)	23.40%	36.20%	24.60%	31%
Tax effect of reorganization		$ 7.2		$ 7.2
Percent impact of reorganization		0.085		0.028

DEBT - Short-term Debt Obligati

DEBT - Short-term Debt Obligations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 124,503	$ 3,810
Revolving credit facility 4.73% to 6.18%
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 123,790	0
Revolving credit facility 4.73% to 6.18% \| Minimum
Short-term Debt [Line Items]
Interest rate (as a percent)	4.73%
Revolving credit facility 4.73% to 6.18% \| Maximum
Short-term Debt [Line Items]
Interest rate (as a percent)	6.18%
Overdrafts
Short-term Debt [Line Items]
Notes payable, revolving credit facility and overdrafts	$ 713	$ 3,810
Overdrafts \| Minimum
Short-term Debt [Line Items]
Interest rate (as a percent)	4.64%
Overdrafts \| Maximum
Short-term Debt [Line Items]
Interest rate (as a percent)	4.71%

DEBT - Narrative (Details)

DEBT - Narrative (Details) € in Millions	Jul. 19, 2023 EUR (€)	Jun. 30, 2021 USD ($) extension	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Jul. 06, 2022	Mar. 07, 2022 USD ($)	Oct. 31, 2020 USD ($)
Line of Credit Facility [Line Items]
Short-term borrowing			$ 124,503,000		$ 3,810,000
Commercial Paper
Line of Credit Facility [Line Items]
Short-term borrowing, maximum borrowing capacity								$ 30,000,000
Short-term borrowing			0		0
Amended Revolving Credit Facility
Line of Credit Facility [Line Items]
Line of credit facility, number of extensions \| extension		2
Line of credit facility, duration of extension (in years)		1 year
Line of credit facility, maximum borrowing capacity		$ 600,000,000
Line of credit facility, increase limit		$ 300,000,000
Long-term line of credit			44,500,000		0
Compensating balance, amount			0
Amended Revolving Credit Facility \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Long-term line of credit			79,300,000	€ 75
Amended Revolving Credit Facility \| Subsidiaries
Line of Credit Facility [Line Items]
Long-term line of credit			$ 0		$ 0
Senior unsecured notes 0.98% due in 2023
Line of Credit Facility [Line Items]
Debt instrument, repaid \| €	€ 100
Interest rate on notes (as a percent)	0.98%
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million
Line of Credit Facility [Line Items]
Aggregate amount of debt issued							$ 400,000,000
Interest rate on notes (as a percent)			3.60%	3.60%		3.60%	3.60%

DEBT - Long-Term Obligations (D

DEBT - Long-Term Obligations (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Jul. 06, 2022	Mar. 07, 2022
Components of the company's debt obligations
Finance Lease Liabilities	$ 24,867	$ 26,934
Unamortized debt issuance costs	(3,997)	(4,558)
Long-term debt and lease obligation, including current maturities	1,046,443	1,171,578
Current maturities of long-term obligations	(366,378)	(118,981)
Total long-term obligations	$ 680,065	1,052,597
Consolidated Leverage Ratio	1.61
Consolidated Interest Coverage Ratio	16.19
Minimum
Components of the company's debt obligations
Consolidated Interest Coverage Ratio	3
Maximum
Components of the company's debt obligations
Consolidated Leverage Ratio	3.50
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031
Components of the company's debt obligations
Long-term debt, gross	$ 15,005	29,167
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031 \| Minimum
Components of the company's debt obligations
Interest rate on notes (as a percent)	0%
Notes payable 0.00% – 2.25%, due in monthly and annual installments through 2031 \| Maximum
Components of the company's debt obligations
Interest rate on notes (as a percent)	2.25%
Senior unsecured notes 1.0%, due in 2023
Components of the company's debt obligations
Long-term debt, gross	$ 0	106,995
Interest rate on notes (as a percent)	1%
Senior unsecured notes 3.4%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 50,000	50,000
Interest rate on notes (as a percent)	3.40%
Senior unsecured notes 3.5%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 100,000	100,000
Interest rate on notes (as a percent)	3.50%
Senior unsecured notes 1.2%, due in 2024
Components of the company's debt obligations
Long-term debt, gross	$ 211,440	213,990
Interest rate on notes (as a percent)	1.20%
Senior unsecured notes 3.6%, due in 2025
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes (as a percent)	3.60%
Senior unsecured notes 3.6%, due in 2026
Components of the company's debt obligations
Long-term debt, gross	$ 125,000	125,000
Interest rate on notes (as a percent)	3.60%
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million
Components of the company's debt obligations
Long-term debt, gross	$ 399,128	$ 399,050
Interest rate on notes (as a percent)	3.60%		3.60%	3.60%
Debt instrument, discount	$ 900

DEBT - Long-Term Maturities (De

DEBT - Long-Term Maturities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Debt Disclosure [Abstract]
Year One	$ 363,408
Year Two	6,368
Year Three	256,200
Year Four	315
Year Five	72
Thereafter	$ 399,210

LEASES - Components of Lease Ex

LEASES - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Components of lease expense:
Operating lease cost	$ 5,150	$ 4,870	$ 15,841	$ 15,605
Finance lease cost:
Amortization of right-of-use assets	908	1,050	2,686	3,307
Interest on lease liabilities	289	307	883	947
Total finance lease cost	1,197	1,357	3,569	4,254
Short-term lease and variable lease costs	$ 5,774	$ 4,226	$ 15,883	$ 11,437

LEASES - Supplemental Cash Flow

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 15,993	$ 15,001
Operating cash flows from finance leases	883	941
Financing cash flows from finance leases	2,377	2,749
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	7,764	13,146
Finance leases	$ 401	$ 919

RETIREMENT AND DEFERRED COMPE_3

RETIREMENT AND DEFERRED COMPENSATION PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
United States
Components of net periodic benefit cost:
Service cost	$ 2,409	$ 3,948	$ 7,228	$ 11,838
Interest cost	2,158	1,742	6,473	5,227
Expected return on plan assets	(3,094)	(3,228)	(9,283)	(9,684)
Amortization of net loss	0	1,668	0	5,003
Amortization of prior service cost	0	0	0	0
Net periodic benefit cost	1,473	4,130	4,418	12,384
Foreign Plans
Components of net periodic benefit cost:
Service cost	1,487	1,775	4,444	5,621
Interest cost	915	330	2,735	1,045
Expected return on plan assets	(589)	(653)	(1,758)	(2,069)
Amortization of net loss	230	403	687	1,280
Amortization of prior service cost	45	35	133	106
Net periodic benefit cost	$ 2,088	$ 1,890	$ 6,241	$ 5,983

RETIREMENT AND DEFERRED COMPE_4

RETIREMENT AND DEFERRED COMPENSATION PLANS - Narrative (Details)	9 Months Ended
	Sep. 30, 2023 USD ($)
Changes in the benefit obligations and plan assets
Minimum funding requirements	$ 0
United States
Changes in the benefit obligations and plan assets
Defined benefit plan, plan assets, contributions by employer	0
Foreign Plans
Changes in the benefit obligations and plan assets
Defined benefit plan, plan assets, contributions by employer	$ 1,000,000

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Changes in Accumulated Other Comprehensive Income by Component (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Accumulated other comprehensive income activity
Balance at the beginning of the period	$ 2,053,935
Other comprehensive (loss) income before reclassifications	(30,655)	$ (179,534)
Amounts reclassified from accumulated other comprehensive income (loss)	581	4,827
Net current-period other comprehensive (loss) income	(30,074)	(174,707)
Balance at the end of the period	2,199,739
Accumulated Other Comprehensive Income/(Loss)
Accumulated other comprehensive income activity
Balance at the beginning of the period	(341,366)	(316,041)
Balance at the end of the period	(371,440)	(490,748)
Foreign Currency
Accumulated other comprehensive income activity
Balance at the beginning of the period	(328,740)	(249,500)
Other comprehensive (loss) income before reclassifications	(28,294)	(182,432)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Net current-period other comprehensive (loss) income	(28,294)	(182,432)
Balance at the end of the period	(357,034)	(431,932)
Defined Benefit Pension Plans
Accumulated other comprehensive income activity
Balance at the beginning of the period	(5,951)	(66,486)
Other comprehensive (loss) income before reclassifications	63	(719)
Amounts reclassified from accumulated other comprehensive income (loss)	581	4,781
Net current-period other comprehensive (loss) income	644	4,062
Balance at the end of the period	(5,307)	(62,424)
Derivatives
Accumulated other comprehensive income activity
Balance at the beginning of the period	(6,675)	(55)
Other comprehensive (loss) income before reclassifications	(2,424)	3,617
Amounts reclassified from accumulated other comprehensive income (loss)	0	46
Net current-period other comprehensive (loss) income	(2,424)	3,663
Balance at the end of the period	$ (9,099)	$ 3,608

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME - Reclassifications From Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amount Reclassified from Accumulated Other Comprehensive Income
Income before Income Taxes	$ 110,049	$ 84,915	$ 294,196	$ 261,012
Tax impact	(25,751)	(30,738)	(72,265)	(80,851)
Changes in cross currency swap: interest component	(9,984)	(9,756)	(29,900)	(30,668)
Changes in cross currency swap: foreign exchange component	3	(2,093)	(1,341)	(3,144)
Net Income	84,298	54,177	221,931	180,161
Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income	194	6,386	581	4,827
Defined Benefit Pension Plans \| Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Amortization of net loss	230	2,071	687	6,283
Amortization of prior service cost	45	35	133	106
Income before Income Taxes	275	2,106	820	6,389
Tax impact	(81)	(530)	(239)	(1,608)
Net Income	194	1,576	581	4,781
Derivatives \| Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Net Income	0	4,810	0	46
Derivatives \| Changes in cross currency swap: interest component \| Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Changes in cross currency swap: interest component	0	(33)	0	(171)
Derivatives \| Changes in cross currency swap: foreign exchange component \| Amount Reclassified from Accumulated Other Comprehensive Income
Amount Reclassified from Accumulated Other Comprehensive Income
Changes in cross currency swap: foreign exchange component	$ 0	$ 4,843	$ 0	$ 217

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands, € in Millions	Jul. 06, 2022 EUR (€)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jul. 06, 2022 USD ($)	Jul. 06, 2022 EUR (€)	Mar. 07, 2022 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		$ 377	$ 1,107
Derivative Liabilities		12,354	9,109
Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		377	1,107
Derivative Liabilities		305	269
Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		0	0
Cross Currency Swap Contract \| Net Investment Hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, term of contract	7 years
Amount hedged				$ 203,000	€ 200
Derivative fixed interest rate				2.5224%	2.5224%
Derivative, annual fixed interest payments receivable				$ 3,700
Cash flow hedge derivative instrument liability at fair value		12,000
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount		51,100
Foreign Exchange Contracts \| Prepaid and other \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Assets		377	1,107
Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities \| Derivatives not Designated as Hedging Instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liabilities		$ 305	$ 269
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.9 million
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt instrument, face amount						$ 400,000
Interest rate on notes (as a percent)		3.60%		3.60%	3.60%	3.60%
Debt instrument, periodic payment \| €	€ 2.5

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Fair Value of Derivative Instruments in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value of Derivative Instruments
Derivative Assets	$ 377	$ 1,107
Derivative Liabilities	12,354	9,109
Derivatives Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivative Liabilities	12,049	8,840
Derivatives Designated as Hedging Instruments \| Foreign Exchange Contracts \| Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	0	0
Derivatives Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	0	0
Derivatives Designated as Hedging Instruments \| Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	12,049	8,840
Derivatives not Designated as Hedging Instruments
Fair Value of Derivative Instruments
Derivative Assets	377	1,107
Derivative Liabilities	305	269
Derivatives not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Prepaid and other
Fair Value of Derivative Instruments
Derivative Assets	377	1,107
Derivatives not Designated as Hedging Instruments \| Foreign Exchange Contracts \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	305	269
Derivatives not Designated as Hedging Instruments \| Cross Currency Swap Contract \| Accounts payable, accrued and other liabilities
Fair Value of Derivative Instruments
Derivative Liabilities	$ 0	$ 0

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Derivative instruments, gain or (loss)
Interest expense	$ (9,984)	$ (9,756)	$ (29,900)	$ (30,668)
Miscellaneous income (expense), net	3	(2,093)	(1,341)	(3,144)
Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain Recognized in Other Comprehensive Income on Derivative	2,707	(1,268)	(2,424)	3,617
Amount of Gain Reclassified from Accumulated Other Comprehensive Income on Derivative	0	(4,810)	0	(46)
Changes in cross currency swap: interest component \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Interest expense	(9,984)		(29,900)
Changes in cross currency swap: interest component \| Interest expense \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain Recognized in Other Comprehensive Income on Derivative	0	(30)	0	229
Amount of Gain Reclassified from Accumulated Other Comprehensive Income on Derivative	0	33	0	171
Changes in cross currency swap: foreign exchange component \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Miscellaneous income (expense), net	3		(1,341)
Changes in cross currency swap: foreign exchange component \| Miscellaneous, net \| Derivatives in Cash Flow Hedging Relationships
Derivative instruments, gain or (loss)
Amount of Gain Recognized in Other Comprehensive Income on Derivative	2,707	(1,238)	(2,424)	3,388
Amount of Gain Reclassified from Accumulated Other Comprehensive Income on Derivative	$ 0	$ (4,843)	$ 0	$ (217)

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Loss Recognized in Income on Derivatives	$ 44	$ (853)	$ (756)	$ (962)
Foreign Exchange Contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of Loss Recognized in Income on Derivatives	$ 44	$ (853)	$ (756)	$ (962)

DERIVATIVE INSTRUMENTS AND HE_7

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Derivative Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Derivative Assets
Gross Amount	$ 377	$ 1,107
Net Amounts Presented in the Statement of Financial Position	377	1,107
Net Amount	377	1,107
Derivative Liabilities
Gross Amount	12,354	9,109
Net Amounts Presented in the Statement of Financial Position	12,354	9,109
Net Amount	$ 12,354	$ 9,109

FAIR VALUE - Fair Value of Fina

FAIR VALUE - Fair Value of Financial Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Oct. 31, 2019
Liabilities
Fair value of long-term obligations	$ 868,700	$ 517,300
Payment for contingent consideration in financing activities		22,750	$ 0
Fusion Acquisition
Liabilities
Percentage of interest acquired						100%
Payment for contingent consideration in financing activities		22,800
Payment of contingent consideration liability in operating activities		2,500
Noble Acquisition
Liabilities
Percentage of interest acquired						100%
Level 3
Liabilities
Contingent consideration obligation	25,310	0
Level 3 \| Enable Injections, Inc.
Assets
Convertible notes					$ 5,000
Level 3 \| Siklus Refill Pte Ltd
Assets
Convertible notes				$ 1,000
Liabilities
Proceeds from collection of note receivable	400
Level 3 \| Fusion Acquisition
Liabilities
Contingent consideration obligation	25,310	0
Level 3 \| Noble Acquisition
Liabilities
Contingent consideration obligation	0	0
Assets and liabilities measured at fair value on recurring basis
Assets
Investment in equity securities	5,297	1,532
Foreign exchange contracts	1,107	377
Convertible notes	5,650	5,650
Total assets at fair value	12,054	7,559
Liabilities
Foreign exchange contracts	269	305
Cross currency swap contract	8,840	12,049
Contingent consideration obligation	25,310
Total liabilities at fair value	34,419	12,354
Assets and liabilities measured at fair value on recurring basis \| Level 1
Assets
Investment in equity securities	5,297	1,532
Foreign exchange contracts	0	0
Convertible notes	0	0
Total assets at fair value	5,297	1,532
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Contingent consideration obligation	0
Total liabilities at fair value	0	0
Assets and liabilities measured at fair value on recurring basis \| Level 2
Assets
Investment in equity securities	0	0
Foreign exchange contracts	1,107	377
Convertible notes	0	0
Total assets at fair value	1,107	377
Liabilities
Foreign exchange contracts	269	305
Cross currency swap contract	8,840	12,049
Contingent consideration obligation	0
Total liabilities at fair value	9,109	12,354
Assets and liabilities measured at fair value on recurring basis \| Level 3
Assets
Investment in equity securities	0	0
Foreign exchange contracts	0	0
Convertible notes	5,650	5,650
Total assets at fair value	5,650	5,650
Liabilities
Foreign exchange contracts	0	0
Cross currency swap contract	0	0
Contingent consideration obligation	25,310
Total liabilities at fair value	$ 25,310	$ 0

FAIR VALUE - Contingent Conside

FAIR VALUE - Contingent Consideration Fair Value (Details) - Level 3 - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration obligation	$ 0	$ 25,310
Fusion Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration obligation	0	25,310
Noble Acquisition
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration obligation	$ 0	$ 0

FAIR VALUE - Roll Forward (Deta

FAIR VALUE - Roll Forward (Details) $ in Thousands	9 Months Ended
FAIR VALUE - Roll Forward (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 25,310
Increase in fair value recorded in earnings	0
Payments	(25,310)
Balance at end of period	$ 0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Insurance claim recovery
Commitments and contingencies
Estimated potential gain contingency	$ 0
Indemnification agreements
Commitments and contingencies
Liabilities recorded under indemnification agreements	0	$ 0
Tax Assessment
Commitments and contingencies
Loss contingency estimate of possible loss	13,000,000
Tax Assessment, Interest and Penalties \| Minimum
Commitments and contingencies
Loss contingency estimate of possible loss	5,000,000
Tax Assessment, Interest and Penalties \| Maximum
Commitments and contingencies
Loss contingency estimate of possible loss	$ 6,000,000

STOCK REPURCHASE PROGRAM (Detai

STOCK REPURCHASE PROGRAM (Details) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Apr. 18, 2019
Stock repurchase program
Common stock repurchased (retired and held in treasury (in shares)	66	181	318	669
Common stock repurchased (retired and held in treasury)	$ 8,300,000	$ 19,200,000	$ 37,300,000	$ 72,300,000
Remaining authorized repurchase amount	$ 70,900,000		$ 70,900,000
Stock Repurchase Program April 18, 2019
Stock repurchase program
Share repurchases authorized amount					$ 350,000,000

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award
Proceeds from stock option exercises	$ 39,742	$ 18,411
Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)	$ 19.84
Received stock options exercise price percentage	110%
Non Executive Officer Employees
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average fair value of stock options granted (in dollars per share)	$ 24.23
Time-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	121,848
RSUs vested (in shares)	181,248
Time-Based RSUs \| Director Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award
RSU's granted (in shares)	10,614
RSUs vested (in shares)	10,589
Performance-Based RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
RSU's granted (in shares)	151,415
RSUs vested (in shares)	99,878
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award
Tax benefit	$ 5,600	6,200
Unrecognized compensation expense	$ 53,000
Weighted-average period cost will be recognized over	1 year 10 months 24 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period (in years)	3 years
Tax benefit	$ 6,800	2,800
Unrecognized compensation expense	$ 3,100
Weighted-average period cost will be recognized over	2 years 2 months 12 days
Expiration period (in years)	10 years
Proceeds from stock option exercises	$ 39,700	$ 18,400

STOCK-BASED COMPENSATION - Assu

STOCK-BASED COMPENSATION - Assumptions Used (Details) - Performance-Based RSUs - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award
Fair value per stock award (in dollars per share)	$ 116.17	$ 141.95
Grant date stock price (in dollars per share)	$ 111.38	$ 114.52
Aptar's stock price expected volatility	20%	20.20%
Expected average volatility of peer companies	39.70%	41.70%
Correlation assumption	33.30%	41.20%
Risk-free interest rate	3.83%	2.04%
Dividend yield assumption	1.36%	1.33%

STOCK-BASED COMPENSATION - Rest

STOCK-BASED COMPENSATION - Restricted Stock Unit Activity (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Time-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) \| shares	426,361
Granted (in shares) \| shares	121,848
Vested (in shares) \| shares	(181,248)
Forfeited (in shares) \| shares	(11,488)
Nonvested outstanding ending balance (in shares) \| shares	355,473
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) \| $ / shares	$ 111.60
Granted, Weighted average grant date fair value (in dollars per share) \| $ / shares	110.30
Vested, Weighted average grant date fair value (in dollars per share) \| $ / shares	104.29
Forfeited, Weighted average grant date fair value (in dollars per share) \| $ / shares	108.05
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) \| $ / shares	$ 115.08
Performance-Based RSUs
Units
Nonvested outstanding beginning balance (in shares) \| shares	610,871
Granted (in shares) \| shares	151,415
Vested (in shares) \| shares	(99,878)
Forfeited (in shares) \| shares	(133,905)
Nonvested outstanding ending balance (in shares) \| shares	528,503
Weighted Average Grant-Date Fair Value
Outstanding, Weighted average grant date fair value begging balance (in dollars per share) \| $ / shares	$ 118.77
Granted, Weighted average grant date fair value (in dollars per share) \| $ / shares	115.69
Vested, Weighted average grant date fair value (in dollars per share) \| $ / shares	89.33
Forfeited, Weighted average grant date fair value (in dollars per share) \| $ / shares	93.61
Outstanding, Weighted average grant date fair value ending balance (in dollars per share) \| $ / shares	$ 129.82

STOCK-BASED COMPENSATION - Comp

STOCK-BASED COMPENSATION - Compensation Expense (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 32,209	$ 31,925
Fair value of units vested	27,662	20,663
Intrinsic value of units vested	32,319	$ 22,329
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	3,875
Compensation expense, net of tax	3,875
Stock options \| Compensation expense (included in SG&A)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	3,561
Stock options \| Compensation expense (included in Cost of sales)
Share-based Compensation Arrangement by Share-based Payment Award
Compensation expense	$ 314

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Stock Awards Plans
Assumptions used to estimate fair value of stock options granted
Dividend yield assumption	1.41%
Expected Stock Price Volatility	16.55%
Risk-free interest rate	3.57%
Expected Life of Option (years)	7 years
Stock options activity
Outstanding at the beginning of the period (in shares)	2,623,944
Granted (in shares)	314,833
Exercised (in shares)	(545,104)
Forfeited or expired (in shares)	(4,130)
Outstanding at the end of the period (in shares)	2,389,543
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 73.34
Options granted, Weighted average exercise price per share (in dollars per share)	116.20
Options exercised, Weighted average exercise price per share (in dollars per share)	69.30
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	83.84
Outstanding at the end of the period (in dollars per share)	$ 79.89
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	2,075,973
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 74.40
Options outstanding, Weighted average remaining contractual term (in years)	3 years 8 months 12 days
Options exercisable, Weighted average remaining contractual term (in years)	2 years 9 months 18 days
Options outstanding, Aggregate intrinsic value (in USD)	$ 108,471
Options exercisable, Aggregate intrinsic value (in USD)	105,629
Options exercised, Intrinsic value, at end of period	$ 27,392	$ 13,618
Director Stock Option Plans
Stock options activity
Outstanding at the beginning of the period (in shares)	51,700
Granted (in shares)	0
Exercised (in shares)	(32,700)
Forfeited or expired (in shares)	0
Outstanding at the end of the period (in shares)	19,000
Stock option weighted average exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 63.91
Options granted, Weighted average exercise price per share (in dollars per share)	0
Options exercised, Weighted average exercise price per share (in dollars per share)	62.36
Options forfeited or expired, Weighted average exercise price per share (in dollars per share)	0
Outstanding at the end of the period (in dollars per share)	$ 66.59
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, Number of options (in shares)	19,000
Options exercisable, Weighted average exercise price per share (in dollars per share)	$ 66.59
Options outstanding, Weighted average remaining contractual term (in years)	7 months 6 days
Options exercisable, Weighted average remaining contractual term (in years)	7 months 6 days
Options outstanding, Aggregate intrinsic value (in USD)	$ 1,115
Options exercisable, Aggregate intrinsic value (in USD)	1,115
Options exercised, Intrinsic value, at end of period	$ 1,978	$ 0

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator
Income available to common stockholders, Diluted	$ 84,296	$ 54,244	$ 222,132	$ 180,292
Income available to common stockholders, Basic	$ 84,296	$ 54,244	$ 222,132	$ 180,292
Denominator (Shares)
Basic (in shares)	65,707	65,322	65,550	65,446
Effect of dilutive stock-based compensation
Diluted (in shares)	67,035	66,581	66,865	66,825
Per Share Amount
Diluted (in dollars per share)	$ 1.26	$ 0.81	$ 3.32	$ 2.70
Basic (in dollars per share)	$ 1.28	$ 0.83	$ 3.39	$ 2.75
Stock options
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	874	884	886	1,034
Restricted stock
Effect of dilutive stock-based compensation
Incremental common shares attributable to dilutive effect of share-based payment arrangements (in shares)	454	375	429	345

SEGMENT INFORMATION - Summary o

SEGMENT INFORMATION - Summary of Reportable Segments (Details) $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 01, 2023 segment	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment Reporting [Abstract]
Number of reportable segments \| segment				3
Number of operating segments realigned \| segment	2
Financial information regarding the Company's reportable segments
Net Sales		$ 892,997	$ 836,860	$ 2,648,970	$ 2,526,335
Acquisition related costs		0	(231)	(255)	(231)
Restructuring initiatives		(6,161)	(2,270)	(19,628)	(2,989)
Net unrealized investment (loss) gain		(5,428)	277	(2,349)	(2,297)
Depreciation and amortization		(62,686)	(57,601)	(184,212)	(174,818)
Interest expense		(9,984)	(9,756)	(29,900)	(30,668)
Interest income		946	752	2,266	2,029
Income before Income Taxes		110,049	84,915	294,196	261,012
Optimization Initiative
Financial information regarding the Company's reportable segments
Restructuring initiatives		(6,586)	(2,254)	(20,069)	(2,254)
Prior Year Initiatives
Financial information regarding the Company's reportable segments
Restructuring initiatives		425	(16)	441	(735)
Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales		389,188	343,397	1,135,934	1,026,090
Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales		323,980	303,046	979,956	929,793
Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales		179,829	190,417	533,080	570,452
Operating segment
Financial information regarding the Company's reportable segments
Net Sales		901,452	846,138	2,678,225	2,562,575
Operating segment \| Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales		389,423	345,079	1,136,544	1,037,120
Adjusted EBITDA		136,344	107,235	371,508	333,793
Restructuring initiatives		(92)	0	(1,657)	0
Operating segment \| Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales		330,467	308,353	1,002,209	947,515
Adjusted EBITDA		41,070	36,563	121,375	112,343
Restructuring initiatives		(2,880)	(2,240)	(12,650)	(2,774)
Operating segment \| Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales		181,562	192,706	539,472	577,940
Adjusted EBITDA		27,607	23,483	81,387	69,020
Restructuring initiatives		(3,098)	(30)	(4,060)	(215)
Intersegment
Financial information regarding the Company's reportable segments
Net Sales		8,455	9,278	29,255	36,240
Intersegment \| Aptar Pharma
Financial information regarding the Company's reportable segments
Net Sales		235	1,682	610	11,030
Intersegment \| Aptar Beauty
Financial information regarding the Company's reportable segments
Net Sales		6,487	5,307	22,253	17,722
Intersegment \| Aptar Closures
Financial information regarding the Company's reportable segments
Net Sales		1,733	2,289	6,392	7,488
Corporate & Other, unallocated
Financial information regarding the Company's reportable segments
Adjusted EBITDA		(11,659)	(13,537)	(45,996)	(45,170)
Restructuring initiatives		$ (91)	$ 0	$ (1,261)	$ 0

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands				9 Months Ended
ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands	Aug. 01, 2023	Mar. 01, 2023	Aug. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow				$ 16,570	$ 4,100
Restricted cash included in prepaid and other				$ 500	$ 1,000
Hengyu acquisition
Acquisitions
Payments to acquire businesses	$ 5,200
iD SCENT
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow		$ 9,400
Cash acquired		$ 1,400
Gulf Closures
Acquisitions
Percentage of interest acquired		80%
Acquisition of businesses, net of cash acquired and release of escrow		$ 1,500
Cash acquired		1,200
Valuation of full company equity of acquired company		3,300
Non-controlling interest value		$ 700
Metaphase
Acquisitions
Acquisition of businesses, net of cash acquired and release of escrow			$ 5,100
Cash acquired			100
Restricted cash included in prepaid and other			$ 1,000

INVESTMENT IN EQUITY SECURITI_3

INVESTMENT IN EQUITY SECURITIES - Schedule of Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Total equity method investments and other investments	$ 48,022	$ 52,308
BTY
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	31,665	31,490
Sonmol
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	4,621	4,997
Desotec GmbH
Schedule of Equity Method Investments [Line Items]
Equity Method Investments:	859	863
PureCycle
Schedule of Equity Method Investments [Line Items]
Other Investments:	1,532	5,297
YAT
Schedule of Equity Method Investments [Line Items]
Other Investments:	5,204	5,508
Loop
Schedule of Equity Method Investments [Line Items]
Other Investments:	2,894	2,894
Others
Schedule of Equity Method Investments [Line Items]
Other Investments:	$ 1,247	$ 1,259

INVESTMENT IN EQUITY SECURITI_4

INVESTMENT IN EQUITY SECURITIES - Narrative (Details) € in Thousands

1 Months Ended

9 Months Ended

12 Months Ended

24 Months Ended

36 Months Ended

Jul. 07, 2021 USD ($)

Apr. 01, 2020 USD ($)

Jan. 01, 2020 USD ($)

Nov. 30, 2020 USD ($)

Sep. 30, 2023 USD ($)

Sep. 30, 2022 USD ($)

Dec. 31, 2009 EUR (€)

Dec. 31, 2020 USD ($)

Dec. 31, 2021 USD ($)

Dec. 31, 2022 USD ($)

Mar. 31, 2022 USD ($)

Mar. 31, 2021

Schedule of Equity Method Investments [Line Items]

Outstanding note receivable

$ 1,500,000

Other Investments

Schedule of Equity Method Investments [Line Items]

Investment impairment

$ 0

BTY

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

49%

Investment in equity securities

$ 32,000,000

Initial lock-up period (in years)

5 years

Second lock-up period (in years)

3 years

Purchases from related party

10,700,000

$ 7,200,000

Accounts payable and other accrued liabilities

$ 2,100,000

$ 1,500,000

BTY | Call Option | Minimum

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

26%

BTY | Call Option | Maximum

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

31%

Sonmol

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

30%

Investment in equity securities

$ 5,000,000

Desotec GmbH

Schedule of Equity Method Investments [Line Items]

Ownership percentage of equity method investment

23%

Investment in equity securities | €

€ 574

Loop | Preferred stock

Schedule of Equity Method Investments [Line Items]

Investment in equity securities

$ 2,900,000

PureCycle

Schedule of Equity Method Investments [Line Items]

Investment ownership percentage

0.01

PureCycle | Preferred stock

Schedule of Equity Method Investments [Line Items]

Investment in equity securities

$ 3,000,000

Increase (decrease) in value of preferred equity stock investment

$ 3,100,000

Purecycle | Preferred stock

Schedule of Equity Method Investments [Line Items]

Equity received in exchange for services

$ 700,000

YAT

Schedule of Equity Method Investments [Line Items]

Investment in equity securities

$ 5,900,000

Investment ownership percentage

0.10

INVESTMENT IN EQUITY SECURITI_5

INVESTMENT IN EQUITY SECURITIES - Purecycle Investment (Details) - USD ($) $ in Thousands	1 Months Ended				9 Months Ended
	Aug. 31, 2023	Jul. 31, 2023	Aug. 31, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Equity Method Investments [Line Items]
Proceeds					$ 5,604	$ 1,599
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Shares Sold (in shares)	261,590	248,859	50,000	107,600
Proceeds	$ 2,945	$ 2,659	$ 511	$ 1,088
Realized Gain	$ 2,220	$ 1,968	$ 372	$ 841

INVESTMENT IN EQUITY SECURITI_6

INVESTMENT IN EQUITY SECURITIES - Net Investment Gain/Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Equity Method Investments [Line Items]
Net investment (loss) gain	$ (1,240)	$ 649	$ 1,839	$ (1,084)
PureCycle \| Preferred stock
Schedule of Equity Method Investments [Line Items]
Net investment (loss) gain	$ (1,240)	$ 649	$ 1,839	$ (1,084)

RESTRUCTURING INITIATIVES - Nar

RESTRUCTURING INITIATIVES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	$ 6,161	$ 2,270	$ 19,628	$ 2,989
Optimization Plan
Restructuring Cost and Reserve [Line Items]
Restructuring initiatives	6,600	$ 2,300	20,069
Cumulative expense incurred	$ 26,300		$ 26,300

RESTRUCTURING INITIATIVES - Res

RESTRUCTURING INITIATIVES - Restructuring Activity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring reserve
Net Charges	$ 6,161	$ 2,270	$ 19,628	$ 2,989
Optimization Plan
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			4,993
Net Charges	6,600	$ 2,300	20,069
Cash Paid			(12,596)
Interest and FX Impact			(97)
Restructuring reserve, balance at the end of the period	12,369		12,369
Employee severance \| Optimization Plan
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			4,993
Net Charges			15,833
Cash Paid			(8,605)
Interest and FX Impact			(105)
Restructuring reserve, balance at the end of the period	12,116		12,116
Professional fees and other costs \| Optimization Plan
Restructuring reserve
Restructuring reserve, balance at the beginning of the period			0
Net Charges			4,236
Cash Paid			(3,991)
Interest and FX Impact			8
Restructuring reserve, balance at the end of the period	$ 253		$ 253